




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/47	A1	(11) International Publication Number: WO 98/55124 (43) International Publication Date: 10 December 1998 (10.12.98)
(21) International Application Number: PCT/EP98/03182 (22) International Filing Date: 25 May 1998 (25.05.98) (30) Priority Data: 60/047,376 2 June 1997 (02.06.97) US (71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE). (72) Inventors; and (75) Inventors/Applicants (for US only): END, David, William [US/US]; 1718 E. Butler Pike, Ambler, PA 19002 (US). ZELESKO, Michael, J. [US/US]; 21 Home Road, Hatboro, PA 19040 (US). (74) Agent: QUAGHEBEUR, Luc; Janssen Pharmaceutica N.V., Patent Dept., Turnhoutseweg 30, B-2340 Beerse (BE).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>

(54) Title: (IMIDAZOL-5-YL)METHYL-2-QUINOLINONE DERIVATIVES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION



(57) Abstract

The invention comprises the use of compounds of formula (I) wherein the dotted line represents an optional bond; X is oxygen or sulfur; R¹ is hydrogen, C₁₋₁₂alkyl, Ar¹, Ar²C₁₋₆alkyl, quinolinylC₁₋₆alkyl, pyridylC₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkyl, mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, aminoC₁₋₆alkyl, or a radical of formula -Alk¹-C(=O)-R₉, -Alk¹-S(O)-R⁹ or -Alk¹-S(O)₂-R⁹; R², R³ and R¹⁶ each independently are hydrogen, hydroxy, halo, cyano, C₁₋₆alkyl, C₁₋₆alkyloxy, hydroxyC₁₋₆alkyloxy, C₁₋₆alkyloxyC₁₋₆alkyloxy, aminoC₁₋₆alkyloxy, mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyloxy, Ar¹, Ar²C₁₋₆alkyl, Ar²oxy, Ar²C₁₋₆alkyloxy, hydroxycarbonyl, C₁₋₆alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C₂₋₆alkenyl; R⁴ and R⁵ each independently are hydrogen, halo, Ar¹, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkyl, C₁₋₆alkyloxy, C₁₋₆alkylthio, amino, hydroxycarbonyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylS(O)C₁₋₆alkyl or C₁₋₆alkylS(O)₂C₁₋₆alkyl; R⁶ and R⁷ each independently are hydrogen, halo, cyano, C₁₋₆alkyl, 4,4-dimethyl-oxazolyl, C₁₋₆alkyloxy or Ar²oxy; R⁸ is hydrogen, C₁₋₆alkyl, cyano, hydroxycarbonyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylcarbonylC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkyloxycarbonylC₁₋₆alkyl, carboxyC₁₋₆alkyl, hydroxyC₁₋₆alkyl, aminoC₁₋₆alkyl, mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, imidazolyl, haloC₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkyl, aminocarbonylC₁₋₆alkyl, or a radical of formula -O-R¹⁰, -S-R¹⁰, -N-R¹¹O¹²; R¹⁷ is hydrogen, halo, cyano, C₁₋₆alkyl, C₁₋₆alkyloxycarbonyl, Ar¹; R¹⁸ is hydrogen, C₁₋₆alkyl, C₁₋₆alkyloxy or halo; R¹⁹ is hydrogen or C₁₋₆alkyl; for the manufacture of a medicament to inhibit smooth muscle cell proliferation.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

(IMIDAZOL-5-YL)METHYL-2-QUINOLINONE DERIVATIVES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION

- 5 The present invention is concerned with a method of use of compounds of formula (I) for the inhibition of smooth muscle cell proliferation.


Proliferation of smooth muscle cells of the arterial wall in response to local injury is an important aetiologic factor of vascular proliferative disorders such as atherosclerosis and restenosis after angioplasty. The incidence of restenosis after percutaneous
10 transluminal coronary angioplasty (PTCA) has been reported to be as high as 45% within three to six months after PTCA treatment (Indolfi et al., *Nature medicine*, 1, 541 - 545 (1995)). Hence, compounds that inhibit smooth muscle cell proliferation can be very useful to prevent or treat vascular proliferative disorders such as atherosclerosis
15 and restenosis.

Heparin is a well known compound to inhibit proliferation of smooth muscle cells after coronary angioplasty (Buchwald et al., *J. Cardiovasc. Pharmacol.*, 28, 481 - 487 (1996)).

20 In our co-pending application PCT/EP96/04515, published on 19 June 1997 as WO-97/21701, the compounds of formula (I), their preparation and compositions containing them are disclosed as farnesyl transferase inhibitors useful for the treatment of *ras* dependent tumors.

25 Unexpectedly, it has been found that the compounds of formula (I) can be used to inhibit smooth muscle cell proliferation. Consequently, the present invention relates to a method of use of compounds of formula (I) for treating vascular proliferative disorders in a warm-blooded animal.

30 The present invention relates to a method of use of compounds of formula (I)



-2-

the pharmaceutically acceptable acid or base addition salts and the stereochemically isomeric forms thereof, wherein

the dotted line represents an optional bond;

5 X is oxygen or sulfur;

R¹ is hydrogen, C₁₋₁₂alkyl, Ar¹, Ar²C₁₋₆alkyl, quinolinylC₁₋₆alkyl, pyridylC₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkyl, mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, aminoC₁₋₆alkyl,

or a radical of formula -Alk¹-C(=O)-R⁹, -Alk¹-S(O)-R⁹ or -Alk¹-S(O)₂-R⁹,

10 wherein Alk¹ is C₁₋₆alkanediyl,

R⁹ is hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, amino, C₁₋₈alkylamino or C₁₋₈alkylamino substituted with C₁₋₆alkyloxycarbonyl;

R², R³ and R¹⁶ each independently are hydrogen, hydroxy, halo, cyano, C₁₋₆alkyl, C₁₋₆alkyloxy, hydroxyC₁₋₆alkyloxy, C₁₋₆alkyloxyC₁₋₆alkyloxy, aminoC₁₋₆alkyloxy,

15 mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyloxy, Ar¹, Ar²C₁₋₆alkyl, Ar²oxy, Ar²C₁₋₆alkyloxy, hydroxycarbonyl, C₁₋₆alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C₂₋₆alkenyl, 4,4-dimethyloxazolyl; or

when on adjacent positions R² and R³ taken together may form a bivalent radical of formula

20 -O-CH₂-O- (a-1),

-O-CH₂-CH₂-O- (a-2),

-O-CH=CH- (a-3),

-O-CH₂-CH₂- (a-4),

-O-CH₂-CH₂-CH₂- (a-5), or

25 -CH=CH-CH=CH- (a-6);

R⁴ and R⁵ each independently are hydrogen, halo, Ar¹, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkyl, C₁₋₆alkyloxy, C₁₋₆alkylthio, amino, hydroxycarbonyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylS(O)C₁₋₆alkyl or C₁₋₆alkylS(O)₂C₁₋₆alkyl;

R⁶ and R⁷ each independently are hydrogen, halo, cyano, C₁₋₆alkyl, C₁₋₆alkyloxy,

30 Ar²oxy, trihalomethyl, C₁₋₆alkylthio, di(C₁₋₆alkyl)amino, or

when on adjacent positions R⁶ and R⁷ taken together may form a bivalent radical of formula

-O-CH₂-O- (c-1), or

-CH=CH-CH=CH- (c-2);

35 R⁸ is hydrogen, C₁₋₆alkyl, cyano, hydroxycarbonyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylcarbonylC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkyloxycarbonylC₁₋₆alkyl, carboxyC₁₋₆alkyl, hydroxyC₁₋₆alkyl, aminoC₁₋₆alkyl, mono- or

-3-

di(C₁₋₆alkyl)aminoC₁₋₆alkyl, imidazolyl, haloC₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkyl, aminocarbonylC₁₋₆alkyl, or a radical of formula

-O-R¹⁰ (b-1),

-S-R¹⁰ (b-2),

5 -N-R¹¹R¹² (b-3),

wherein R¹⁰ is hydrogen, C₁₋₆alkyl, C₁₋₆alkylcarbonyl, Ar¹, Ar²C₁₋₆alkyl, C₁₋₆alkyloxycarbonylC₁₋₆alkyl, or a radical or formula -Alk²-OR¹³ or -Alk²-NR¹⁴R¹⁵;

R¹¹ is hydrogen, C₁₋₁₂alkyl, Ar¹ or Ar²C₁₋₆alkyl;

10 R¹² is hydrogen, C₁₋₆alkyl, C₁₋₁₆alkylcarbonyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylaminocarbonyl, Ar¹, Ar²C₁₋₆alkyl, C₁₋₆alkylcarbonylC₁₋₆alkyl, a natural amino acid, Ar¹carbonyl, Ar²C₁₋₆alkylcarbonyl, aminocarbonylcarbonyl, C₁₋₆alkyloxyC₁₋₆alkylcarbonyl, hydroxy, C₁₋₆alkyloxy, aminocarbonyl, di(C₁₋₆alkyl)aminoC₁₋₆alkylcarbonyl, amino, C₁₋₆alkylamino, C₁₋₆alkylcarbonylamino, or a radical or formula -Alk²-OR¹³ or -Alk²-NR¹⁴R¹⁵;

wherein Alk² is C₁₋₆alkanediyl;

R¹³ is hydrogen, C₁₋₆alkyl, C₁₋₆alkylcarbonyl, hydroxyC₁₋₆alkyl, Ar¹ or Ar²C₁₋₆alkyl;

20 R¹⁴ is hydrogen, C₁₋₆alkyl, Ar¹ or Ar²C₁₋₆alkyl;

R¹⁵ is hydrogen, C₁₋₆alkyl, C₁₋₆alkylcarbonyl, Ar¹ or Ar²C₁₋₆alkyl;

R¹⁷ is hydrogen, halo, cyano, C₁₋₆alkyl, C₁₋₆alkyloxycarbonyl, Ar¹;

R¹⁸ is hydrogen, C₁₋₆alkyl, C₁₋₆alkyloxy or halo;

R¹⁹ is hydrogen or C₁₋₆alkyl;

25 Ar¹ is phenyl or phenyl substituted with C₁₋₆alkyl, hydroxy, amino, C₁₋₆alkyloxy or halo; and

Ar² is phenyl or phenyl substituted with C₁₋₆alkyl, hydroxy, amino, C₁₋₆alkyloxy or halo; for the inhibition of smooth muscle cell proliferation.

30 R⁴ or R⁵ may also be bound to one of the nitrogen atoms in the imidazole ring. In that case the hydrogen on the nitrogen is replaced by R⁴ or R⁵ and the meaning of R⁴ and R⁵ when bound to the nitrogen is limited to hydrogen, Ar¹, C₁₋₆alkyl, hydroxy-C₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylS(O)C₁₋₆alkyl, C₁₋₆alkylS(O)₂C₁₋₆alkyl.

35

As used in the foregoing definitions and hereinafter halo defines fluoro, chloro, bromo and iodo; C₁₋₆alkyl defines straight and branched chained saturated hydrocarbon

-4-

radicals having from 1 to 6 carbon atoms such as, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl and the like; C₁₋₈alkyl encompasses the straight and branched chained saturated hydrocarbon radicals as defined in C₁₋₆alkyl as well as the higher homologues thereof containing 7 or 8 carbon atoms such as, for example heptyl or octyl; C₁₋₁₂alkyl again encompasses C₁₋₈alkyl and the higher homologues thereof containing 9 to 12 carbon atoms, such as, for example, nonyl, decyl, undecyl, dodecyl; C₁₋₁₆alkyl again encompasses C₁₋₁₂alkyl and the higher homologues thereof containing 13 to 16 carbon atoms, such as, for example, tridecyl, tetradecyl, pentadecyl and hexadecyl; C₂₋₆alkenyl defines straight and branched chain hydrocarbon radicals containing one double bond and having from 2 to 6 carbon atoms such as, for example, ethenyl, 2-propenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-butenyl, and the like; C₁₋₆alkanediyl defines bivalent straight and branched chained saturated hydrocarbon radicals having from 1 to 6 carbon atoms, such as, for example, methylene, 1,2-ethanediyl, 1,3-propanediyl, 1,4-butanediyl, 1,5-pentanediyl, 1,6-hexanediyl and the branched isomers thereof. The term "C(=O)" refers to a carbonyl group, "S(O)" refers to a sulfoxide and "S(O)₂" to a sulfon. The term "natural amino acid" refers to a natural amino acid that is bound via a covalent amide linkage formed by loss of a molecule of water between the carboxyl group of the amino acid and the amino group of the remainder of the molecule. Examples of natural amino acids are glycine, alanine, valine, leucine, isoleucine, methionine, proline, phenylalanine, tryptophan, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine.

The pharmaceutically acceptable acid or base addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid and non-toxic base addition salt forms which the compounds of formula (I) are able to form. The compounds of formula (I) which have basic properties can be converted in their pharmaceutically acceptable acid addition salts by treating said base form with an appropriate acid. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic (*i.e.* butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, *p*-toluenesulfonic, cyclamic, salicylic, *p*-aminosalicylic, pamoic and the like acids.

The compounds of formula (I) which have acidic properties may be converted in their pharmaceutically acceptable base addition salts by treating said acid form with a

-5-

5 suitable organic or inorganic base. Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. the benzathine, *N*-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.

10 The terms acid or base addition salt also comprise the hydrates and the solvent addition forms which the compounds of formula (I) are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.

15 The term stereochemically isomeric forms of compounds of formula (I), as used hereinbefore, defines all possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which the compounds of formula (I) may possess. Unless otherwise
20 mentioned or indicated, the chemical designation of a compound encompasses the mixture of all possible stereochemically isomeric forms which said compound may possess. Said mixture may contain all diastereomers and/or enantiomers of the basic molecular structure of said compound. All stereochemically isomeric forms of the compounds of formula (I) both in pure form or in admixture with each other are
25 intended to be embraced within the scope of the present invention.

Some of the compounds of formula (I) may also exist in their tautomeric forms. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention.

25 Whenever used hereinafter, the term "compounds of formula (I)" is meant to include also the pharmaceutically acceptable acid or base addition salts and all stereoisomeric forms.

30 Preferably the substituent R^{18} is situated on the 5 or 7 position of the quinolinone moiety and substituent R^{19} is situated on the 8 position when R^{18} is on the 7-position.

Interesting compounds are these compounds of formula (I) wherein X is oxygen.

35 Also interesting compounds are these compounds of formula (I) wherein the dotted line represents a bond, so as to form a double bond.

Another group of interesting compounds are those compounds of formula (I) wherein R^1 is hydrogen, C_{1-6} alkyl, C_{1-6} alkyloxy C_{1-6} alkyl, di(C_{1-6} alkyl)amino C_{1-6} alkyl, or a

-6-

radical of formula $-\text{Alk}^1-\text{C}(=\text{O})-\text{R}^9$, wherein Alk^1 is methylene and R^9 is C_{1-8} alkylamino substituted with C_{1-6} alkyloxycarbonyl.

5 Still another group of interesting compounds are those compounds of formula (I) wherein R^3 is hydrogen or halo; and R^2 is halo, C_{1-6} alkyl, C_{2-6} alkenyl, C_{1-6} alkyloxy, trihalomethoxy or hydroxy C_{1-6} alkyloxy.

10 A further group of interesting compounds are those compounds of formula (I) wherein R^2 and R^3 are on adjacent positions and taken together to form a bivalent radical of formula (a-1), (a-2) or (a-3).

A still further group of interesting compounds are those compounds of formula (I) wherein R^5 is hydrogen and R^4 is hydrogen or C_{1-6} alkyl.

15 Yet another group of interesting compounds are those compounds of formula (I) wherein R^7 is hydrogen; and R^6 is C_{1-6} alkyl or halo, preferably chloro, especially 4-chloro.

20 A particular group of compounds are those compounds of formula (I) wherein R^8 is hydrogen, hydroxy, halo C_{1-6} alkyl, hydroxy C_{1-6} alkyl, cyano C_{1-6} alkyl, C_{1-6} alkyloxycarbonyl C_{1-6} alkyl, imidazolyl, or a radical of formula $-\text{NR}^{11}\text{R}^{12}$ wherein R^{11} is hydrogen or C_{1-12} alkyl and R^{12} is hydrogen, C_{1-6} alkyl, C_{1-6} alkyloxy, hydroxy, C_{1-6} alkyloxy C_{1-6} alkylcarbonyl, or a radical of formula $-\text{Alk}^2-\text{OR}^{13}$ wherein R^{13} is hydrogen or C_{1-6} alkyl.

25 Preferred compounds are those compounds wherein R^1 is hydrogen, C_{1-6} alkyl, C_{1-6} alkyloxy C_{1-6} alkyl, di(C_{1-6} alkyl)amino C_{1-6} alkyl, or a radical of formula $-\text{Alk}^1-\text{C}(=\text{O})-\text{R}^9$, wherein Alk^1 is methylene and R^9 is C_{1-8} alkylamino substituted with C_{1-6} alkyloxycarbonyl; R^2 is halo, C_{1-6} alkyl, C_{2-6} alkenyl, C_{1-6} alkyloxy, trihalomethoxy, hydroxy C_{1-6} alkyloxy or Ar^1 ; R^3 is hydrogen; R^4 is methyl bound to the nitrogen in 3-position of the imidazole; R^5 is hydrogen; R^6 is chloro; R^7 is hydrogen; R^8 is hydrogen, hydroxy, halo C_{1-6} alkyl, hydroxy C_{1-6} alkyl, cyano C_{1-6} alkyl, C_{1-6} alkyloxycarbonyl C_{1-6} alkyl, imidazolyl, or a radical of formula $-\text{NR}^{11}\text{R}^{12}$ wherein R^{11} is hydrogen or C_{1-12} alkyl and R^{12} is hydrogen, C_{1-6} alkyl, C_{1-6} alkyloxy, C_{1-6} alkyloxy C_{1-6} alkylcarbonyl, or a radical of formula $-\text{Alk}^2-\text{OR}^{13}$ wherein R^{13} is C_{1-6} alkyl; R^{17} is hydrogen and R^{18} is hydrogen.

30


35

-7-

Most preferred compounds are

- 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1*H*-imidazol-5-yl)methyl]-1-methyl-2(1*H*)-quinolinone,
 6-[amino(4-chlorophenyl)-1-methyl-1*H*-imidazol-5-ylmethyl]-4-(3-chlorophenyl)-
 5 1-methyl-2(1*H*)-quinolinone;
 6-[(4-chlorophenyl)hydroxy(1-methyl-1*H*-imidazol-5-yl)methyl]-4-(3-ethoxyphenyl)-1-methyl-2(1*H*)-quinolinone;
 6-[(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-4-(3-ethoxyphenyl)-1-methyl-2(1*H*)-quinolinone monohydrochloride monohydrate;
 10 6-[amino(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-4-(3-ethoxyphenyl)-1-methyl-2(1*H*)-quinolinone,
 6-amino(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-1-methyl-4-(3-propylphenyl)-2(1*H*)-quinolinone; a stereoisomeric form thereof or a pharmaceutically acceptable acid or base addition salt; and
 15 (+)-6-[amino(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1*H*)-quinolinone; or a pharmaceutically acceptable acid addition salt thereof.


The compounds of formula (I), wherein X is oxygen, said compounds being represented
 20 by formula (I-a), may be prepared by hydrolysing an intermediate ether of formula (II), wherein R is C₁₋₆alkyl, according to art-known methods, such as stirring the intermediate of formula (II) in an aqueous acid solution. An appropriate acid is for instance hydrochloric acid. Subsequently the resulting quinolinone wherein R¹ is hydrogen may be transformed into a quinolinone, wherein R¹ has a meaning as defined
 25 hereinabove apart from hydrogen, by art-known *N*-alkylation.




The compounds of formula (I), wherein R⁸ is hydroxy, said compounds being referred
 30 to as compounds of formula (I-b) may be prepared by reacting an intermediate ketone of formula (III) with a intermediate of formula (IV-a), wherein P is an optional protective group such as, for example, a sulfonyl group, e.g. a dimethylamino sulfonyl

-8-


- group, which can be removed after the addition reaction. Said reaction requires the presence of a suitable strong base, such as, for example, butyl lithium in an appropriate solvent, such as, for example, tetrahydrofuran and the presence an appropriate silanederivative, such as, for example, triethylchlorosilane. During the work-up
- 5 procedure an intermediate silane derivative is hydrolyzed. Other procedures with protective groups analogous to silanederivatives can also be applied.



- 10 Compounds of formula (I-b-1), being compounds of formula (I-b) wherein the dotted line is a bond and R¹ is hydrogen, can be prepared by reacting an intermediate of formula (XXI) with an intermediate of formula (IV-a), as described hereinabove for the synthesis of compounds of formula (I-b). The thus obtained intermediate of formula
- (XXII) undergoes ring opening of the isoxazole moiety by stirring it with an acid, such
- 15 as, e.g. TiCl₃, in the presence of water. Subsequent treatment of an intermediate of formula (XXIII) with a suitable reagent such as, e.g. R¹⁷CH₂COCl or R¹⁷CH₂COOC₂H₅, yields either directly a compound of formula (I-b-1) or an intermediate which can be converted to a compound of formula (I-b-1) by treatment
- 20 with a base such as, e.g. potassium *tert*-butoxide.




-9-



Intermediates of formula (XXI) can conveniently be prepared by treating an intermediate of formula (XVI), described hereinafter, under acidic conditions.

5 Compounds of formula (I) wherein R^8 is a radical of formula $-N-R^{11}R^{12}$, said compounds being represented by formula (I-g) may be prepared by reacting an intermediate of formula (XIII), wherein W is an appropriate leaving group such as, for example, halo, with a reagent of formula (XIV). Said reaction may be performed by

10 stirring the reactants in an appropriate solvent such as, for example, tetrahydrofuran.



15 The compounds of formula (I) may also be prepared by converting compounds of formula (I) into other compounds of formula (I).

Compounds wherein the dotted line represents a bond can be converted into compounds wherein the dotted line does not represent a bond, by art-known hydrogenation methods. Vice versa, compounds wherein the dotted line does not represent a bond may


20 be converted into compounds wherein the dotted line represents a bond by art-known oxidation reactions.

Compounds of formula (I) wherein R^8 is hydroxy, said compounds being represented by formula (I-b) may be converted into compounds of formula (I-c), wherein R^{8a} has the meaning of R^{10} except for hydrogen, by art-know *O*-alkylation or *O*-acylation

25 reactions; such as, for instance, reacting the compound of formula (I-b) with an

-10-

alkylating reagent such as $R^{8a}\text{-W}$ in appropriate conditions, such as, for example, a dipolar aprotic solvent, e.g. DMF, in the presence of a base, e.g. sodium hydride. W is a suitable leaving group, such as, for example, halo or a sulfonyl group.



As an alternative to the above reaction procedure, compounds of formula (I-c) may also be prepared by reacting an intermediate of formula (I-b) with a reagent of formula $R^{8a}\text{-OH}$ in acidic medium.

10

Compounds of formula (I-b) may also be converted into compounds of formula (I-g), wherein R^{11} is hydrogen and R^{12} is C_{1-16} alkylcarbonyl, by reacting compounds of formula (I-b) in acidic medium, such as sulfuric acid, with C_{1-16} alkyl-CN in a Ritter type reaction. Further, compounds of formula (I-b) may also be converted into compounds of formula (I-g), wherein R^{11} and R^{12} are hydrogen, by reacting compounds (I-b) with ammonium acetate and subsequent treatment with NH_3 (aq.).


15

Compounds of formula (I-b) may also be converted into compounds of formula (I-d), wherein R^8 is hydrogen, by submitting the compounds of formula (I-b) to appropriate reducing conditions, such as, stirring in trifluoroacetic acid in the presence of an appropriate reducing agent, such as sodium borohydride or alternatively stirring the compounds of formula (I-b) in acetic acid in the presence of formamide. Furthermore, compounds of formula (I-d) wherein R^8 is hydrogen may be converted into compounds of formula (I-e) wherein R^{8b} is C_{1-6} alkyl by reacting compounds of formula (I-d) with a reagent of formula (V) in an appropriate solvent, such as, for instance, diglyme in the presence of a base such as, for example, potassium butoxide.


20

25


-11-



- A compound of formula (I-f), defined as a compound of formula (I) wherein X is sulfur may be prepared by reacting the corresponding compound of formula (I-a), with a reagent like phosphorus pentasulfide or Lawesson's reagent in a suitable solvent such as, for example, pyridine.



- Compounds of formula of formula (I), wherein R¹ is hydrogen and X is oxygen, said compounds being defined as compounds of formula (I-a-1) may be prepared by reacting a nitron of formula (VI) with the anhydride of a carboxylic acid, such as, for example, acetic anhydride, thus forming the corresponding ester on the 2 position of the quinoline moiety. Said quinoline ester can be hydrolyzed *in situ* to the corresponding quinolinone using a base such as, for example, potassium carbonate.




- Alternatively, compounds of formula (I-a-1) can be prepared by reacting a nitron of formula (VI) with a sulfonyl containing electrophilic reagent such as, for example,

-12-

p-toluenesulfonylchloride in the presence of a base such as, for example, aqueous potassium carbonate. The reaction initially involves the formation of a 2-hydroxy-quinoline derivative which is subsequently tautomerized to the desired quinolinone derivative. The application of art-known conditions of phase transfer catalysis may enhance the rate of the reaction.

Compounds of formula (I-a-1) may also be prepared by an intramolecular photochemical rearrangement of compounds of formula (VI). Said rearrangement can be carried out by dissolving the reagents in a reaction-inert solvent and irradiating at a wavelength of 366 nm. It is advantageous to use degassed solutions and to conduct the reaction under an inert atmosphere such as, for example, oxygen free argon or nitrogen gas, in order to minimize undesired side reactions or reduction of quantum yield.




The compounds of formula (I) may also be converted into each other via art-known reactions or functional group transformations. A number of such transformations are already described hereinabove. Other examples are hydrolysis of carboxylic esters to the corresponding carboxylic acid or alcohol; hydrolysis of amides to the corresponding carboxylic acids or amines; hydrolysis of nitriles to the corresponding amides; amino groups on imidazole or phenyl may be replaced by a hydrogen by art-known diazotation reactions and subsequent replacement of the diazo-group by hydrogen; alcohols may be converted into esters and ethers; primary amines may be converted into secondary or tertiary amines; double bonds may be hydrogenated to the corresponding single bond.


Intermediates of formula (III) may be prepared by reacting a quinolinone derivative of formula (VIII) with an intermediate of formula (IX) or a functional derivative thereof under appropriate conditions, such as, for example, a strong acid, e.g. polyphosphoric acid in an appropriate solvent. The intermediate of formula (VIII) may be formed by cyclization of an intermediate of formula (VII) by stirring in the presence of a strong acid, e.g. polyphosphoric acid. Optionally said cyclization reaction may be followed by

-13-


an oxidation step, which can be performed by stirring the intermediate formed after cyclization in an appropriate solvent, such as, for example, a halogenated aromatic solvent, e.g. bromobenzene, in the presence of an oxidizing agent, e.g. bromine or iodine. At this stage it may also be appropriate to change the R¹ substituent by art-known functional group transformation reaction.




Intermediates of formula (III-a-1), being intermediates of formula (III) wherein the dotted line is a bond, R¹ and R¹⁷ are hydrogen and X is oxygen, can be prepared starting from an intermediate of formula (XVII), which is conveniently prepared by protecting the corresponding ketone. Said intermediate of formula (XVII) is stirred with an intermediate of formula (XVIII) in the presence of a base such as sodium hydroxide, in an appropriate solvent, such as an alcohol, e.g. methanol. The thus obtained intermediate of formula (XVI) undergoes hydrolysis of the ketal and ring opening of the isoxazole moiety by stirring the intermediate of formula (XVI) with an acid, such as for example, TiCl₃, in the presence of water. Subsequently acetic anhydride is used to prepare an intermediate of formula (XV), which undergoes ring closure in the presence of a base such as, for example, potassium *tert*-butoxide.



-14-



Intermediates of formula (III-a-1) can easily be converted to intermediates of formula (III-a), defined as intermediates of formula (III) wherein the dotted line represents a bond, X is oxygen, R^{17} is hydrogen and R^1 is other than hydrogen, using art-known *N*-alkylation procedures.




10 An alternative way to prepare intermediates of formula (III-a-1), wherein X is oxygen and R^1 is hydrogen, starts from an intermediate of formula (XVI), which is conveniently converted to intermediates of formula (XIX) using catalytic hydrogenation conditions, e.g. by using hydrogen gas and palladium on carbon in a reaction-inert solvent such as, e.g. tetrahydrofuran. Intermediates of formula (XIX) are converted to


15 intermediates of formula (XX) by submitting intermediates (XIX) to an acetylation reaction, e.g. by treatment with the anhydride of a carboxylic acid, e.g. acetic anhydride in a reaction-inert solvent, e.g. toluene, and subsequent treatment with a base such as, e.g. potassium *tert*-butoxide in a reaction-inert solvent, e.g. 1,2-dimethoxyethane. Intermediates of formula (III-a-1) can be obtained by treating intermediates of formula

20 (XX) in acidic conditions.


-15-



Intermediates of formula (II) may be prepared by reacting an intermediate of formula (X), wherein W is an appropriate leaving group, such as, for example, halo, with an intermediate ketone of formula (XI). This reaction is performed by converting the intermediate of formula (X) into a organometallic compound, by stirring it with a strong base such as butyl lithium and subsequently adding the intermediate ketone of formula (XI). Although this reaction gives at first instance a hydroxy derivative (i.e. R⁸ is hydroxy), said hydroxy derivative can be converted into other intermediates wherein R⁸ has another definition by performing art-known (functional group) transformations.



The intermediate nitrones of formula (VI) may be prepared by *N*-oxidizing quinoline derivatives of formula (XII) with an appropriate oxidizing agent such as, for example, *m*-chloro-peroxybenzoic acid or H₂O₂ in an appropriate solvent such as, for example, dichloromethane.



Said *N*-oxidation may also be carried out on a precursor of a quinoline of formula (XII).

5 The intermediates of formula (XII) are supposed to be metabolized *in vivo* into compounds of formula (I) via intermediates of formula (VI). Hence, intermediates of formula (XII) and (VI) may act as prodrugs of compounds of formula (I).

10 The compounds of formula (I) and some of the intermediates have at least one stereogenic center in their structure. This stereogenic center may be present in a R or a S configuration.

15 The compounds of formula (I) as prepared in the hereinabove described processes are generally racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures. The racemic compounds of formula (I) may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali. An alternative manner of separating the enantiomeric forms of the compounds of formula (I) involves liquid chromatography using a chiral stationary
20 phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure
25 starting materials.

This invention provides a method of use of compounds of formula (I) to inhibit the proliferation of smooth muscle cells, as illustrated by pharmacological example C.1.

30 Hence, the compounds of formula (I) can be used for the manufacture of a medicament for the inhibition of smooth muscle cell proliferation and consequently the use for the manufacture of a medicament for the treatment of vascular proliferative disorders such as atherosclerosis and restenosis is also provided.

35 It has been proposed in literature that the mechanism behind smooth muscle cell proliferation involves the loss of normal regulation of cellular growth, a process wherein *ras* proteins plays a significant role. Accordingly, it has been suggested that compounds having farnesyl transferase inhibiting properties, can be useful to prevent

-17-

smooth muscle cell proliferation after vascular injury (Indolfi et al., *Nature medicine*, 1, 541 - 545 (1995) and Irani et al., *Biochemical and biophysical research Communications*, 202, 1252 - 1258, (1994)).

- 5 Atherosclerosis is a disorder characterized by the deposition of fatty substances in and fibrosis of the inner layer of the arteries.

Restenosis is the narrowing of tubular passageways of a subject after the tubular walls have been traumatized. This can be caused by uncontrolled cellular proliferation of
10 neointimal tissue which often is a complication due to the use of revascularization techniques such as, e.g. saphenous vein bypass grafting, endarterectomy, percutaneous transluminal coronary angioplasty (PTCA) and the like. Restenosis refers to a worsening or recurrence of luminal stenosis in an artery which is characterized by a hyperplasia of cells of the arterial wall. In this respect, restenosis differs notably from
15 an occlusion of the artery by an arterial atherosclerotic plaque or occlusion by thrombus.

Restenosis is not restricted or limited to the coronary arteries. It can also occur in for example peripheral vascular systems.

20 Angioplasty is a technique whereby an artery clogged by an atherosclerotic plaque and/or thrombus is mechanically cleared. Such a clogged or blocked artery prevents adequate blood flow. Angioplasty procedures are much less invasive and much less traumatic than conventional alternatives such as coronary bypass surgery and have
25 gained widespread acceptance as a means of obtaining dilation or clearance of arteries. In conventional angioplasty procedures, a small balloon-tipped catheter is introduced into an artery, often using a guide wire or a catheter tube in which a collapsed balloon may be positioned at one more points of arterial stenosis, *i.e.* narrowing. Once positioned within the blockage, the balloon is inflated, thereby stretching and/or
30 fracturing the blockage and enlarging the lumen (opening) of the artery. After the balloon is deflated and removed from the artery, the artery's internal diameter is generally larger, resulting in restoration of blood flow. These balloon and catheter assemblies are often referred to as coronary balloon dilation catheters. However, said angioplasty procedures involve risk of both local and systemic thromboembolic effects,
35 tearing of an arterial wall and restenosis.

Restenosis after balloon angioplasty is also referred to as 'percutaneous transluminal coronary angioplasty restenosis' and is characterized by the return of blockage in the

-18-

artery due to neointimal formation of a layer of smooth muscle cells in the intima after balloon injury.

Accordingly, the present invention provides a method of treating vascular proliferative disorders in a warm-blooded animal, such as atherosclerosis or restenosis, which comprises administering to said warm-blooded animal a prophylactically or therapeutically effective amount of a compound of formula (I).

The present invention provides further a method of inhibiting smooth muscle cell proliferation in a warm-blooded animal which comprises administering to said warm-blooded animal a prophylactically or therapeutically effective amount of a compound of formula (I).

Balloon angioplasty can be followed by a mechanical/surgical procedure known as intravascular stenting, a procedure in which an expandable metallic sleeve, or scaffold, *i.e.* a stent, is placed within the artery after angioplasty. However, after the insertion of the stent a disorder known as 'coronary artery stent restenosis' can occur whereby the blockage in the artery returns due to neointimal formation of a layer of smooth muscle cells in the intima. Therefore, it may be advantageous to cover or coat said stent with a coating material which comprises a compounds of formula (I) in order to inhibit smooth muscle cell proliferation. Hence, in an aspect, this invention also provides stents covered or coated with a coating material which comprises an amount of a compound of formula (I) effective in preventing, treating or reducing smooth muscle cell proliferation. Commercially available stents are e.g. balloon expandable stents such as, e.g. Palmaz-Schatz™ stent, Strecker™ stent and Gianturco-Roubin™ stent, and self expandable stents such as, e.g. Gianturco™ expandable wire stent and Wallstent™, other stents are Palmaz-Schatz Crown™, Cross-Flex™, ACS Multi-Link™, Nir™, Micro Stent II™ and Wiktor™.

In a way, the invention also relates to catheters, or other transluminal devices coated or covered with a coating material which comprises an amount of a compound of formula (I) effective in preventing, treating or reducing smooth muscle cell proliferation.

The metallic surface of a stent can be coated in a number of ways. The surface can be prepared by a two-step procedure including covalently linking an organosilane having amine reactive sites, with the surface of the metallic member, typically through a metal oxide thereof. Also, an organosilane having a vinyl functionality pendant from the

-19-

surface can be used. Thereafter, a biocompatible coating material can be covalently linked to the organosilane coating.

5 The coating layer comprising an amount of a compound of formula (I) may also be applied as a mixture of a polymeric precursor and a compound of formula (I) which is finely divided or dissolved in a polymer solvent or vehicle which is thereafter cured in situ.

10 The coating may be applied by dipping or spraying using evaporative solvent materials of relatively high vapor pressure to produce the desired viscosity and coating thickness. The coating further is one which adheringly conforms to the surface of the filaments of the open structure of the stent so that the open lattice nature of the structure of the braid or other pattern is preserved in the coated device.

15 The major constituent of the stent coating should have elastomeric properties. The stent coating is preferably a suitable hydrophobic biostable elastomeric material which does not degrade and which minimizes tissue rejection and tissue inflammation and one which will undergo encapsulation by tissue adjacent the stent implantation site. Polymers suitable for such coatings include silicones (e.g. polysiloxanes and substituted
20 polysiloxanes), polyurethanes, thermoplastic elastomers in general, ethylene vinyl acetate copolymers, polyolefin elastomers, and EPDM rubbers.

The loading of the stent coating with the compound of formula (I) may vary. The desired release rate profile can be tailored by varying the coating thickness, the radial
25 distribution, the mixing method, the amount of said compound of formula (I), and the crosslink density of the polymeric material.

Methods for coating stents are described in, e.g. WO-96/32907, US-5,607,475, US-5,356,433, US-5,213,898, US-5,049,403, US-4,807,784 and US-4,565,740.
30

Stents are made of a biocompatible material such as, e.g. stainless steel, tantalum, titanium, nitinol, gold, platinum, inconel, iridium, silver, tungsten, or another biocompatible metal, or alloys of any of these. Stainless steel and tantalum are particularly useful. Said stent can be covered by one or more layers of a biocompatible
35 coating material such as, e.g. carbon, carbon fiber, cellulose acetate, cellulose nitrate, silicone, parylene, parylene derivatives, polyethylene terephthalate, polyurethane, polyamide, polyester, polyorthoester, polyanhydride, polyether sulfone, polycarbonate, polypropylene, high molecular weight polyethylene, polytetrafluoroethylene, or another

-20-

biocompatible material, or mixture or copolymers of these. Parylene is both a generic name for a known group of polymers based on *p*-xylene and made by vapor phase polymerization, and a name for the unsubstituted one of such polymers. Said one or more layers of biocompatible material comprise a compound of formula (I) of the present invention and advantageously provide a controlled release of said compound of formula (I) effective in preventing, treating or reducing smooth muscle cell proliferation. Said one or more layers of biocompatible material can further comprise bioactive materials such as, e.g. heparin or another thrombin inhibitor, hirudin, hirulog, argatroban, D-phenylalanyl-L-poly-L-arginyl chloromethyl ketone, or another antithrombogenic agent, or mixtures thereof; urokinase, streptokinase, a tissue plasminogen activator, or another thrombolytic agent, or mixtures thereof; a fibrinolytic agent; a vasospasm inhibitor; a calcium channel blocker, a nitrate, nitric oxide, a nitric oxide promoter or another vasodilator; an antimicrobial agent or antibiotic; aspirin, ticlopidine, a glycoprotein IIb/IIIa inhibitor or another inhibitor of surface glycoprotein receptors, or another antiplatelet agent; colchicine or another antimitotic, or another microtubule inhibitor; a retinoid or another antisecretory agent; cytochalasin or another actin inhibitor; deoxyribonucleic acid, an antisense nucleotide or another agent for molecular genetic intervention; methotrexate or another antimetabolite or antiproliferative agent; an anticancer chemotherapeutic agent; dexamethasone, dexamethasone sodium phosphate, dexamethasone acetate or another dexamethasone derivative, or another anti-inflammatory steroid or non-steroidal antiinflammatory agent; cyclosporin or another immunosuppressive agent; trapidal (a PDGF antagonist), angiopeptin (a growth hormone antagonist), an anti-growth factor antibody, or another growth factor antagonist; dopamine, bromocriptine mesylate, pergolide mesylate or another dopamine agonist; captopril, enalapril or another angiotensin converting enzyme (ACE) inhibitor; ascorbic acid, alphotocopherol, superoxide dismutase, deferoxamine, a 21-aminosteroid (lasaroid) or another free radical scavenger; or a mixture of any of these.

Hence, the present invention further provides a method of treating vascular proliferative disorders in a warm-blooded animal, such as percutaneous transluminal coronary angioplasty restenosis or coronary artery stent restenosis, which comprises administering to said warm-blooded animal a prophylactically or therapeutically effective amount of a compound of formula (I).

In particular said warm-blooded animal is a mammal or more specifically a human.

As is known to those skilled in the art, a prophylactically or therapeutically effective amount varies with the type of therapeutic agent. It is known to those skilled in the art how to determine a prophylactically or therapeutically effective amount of a suitable therapeutic agent.

5

In view of their useful pharmacological properties, the subject compounds may be formulated into various pharmaceutical forms for administration purposes.

To prepare the pharmaceutical compositions of this invention, an effective amount of a particular compound, in base or acid addition salt form, as the active ingredient is
10 combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form,
15 any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules
20 represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, to aid solubility for example, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose
25 solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which
30 additives do not cause a significant deleterious effect to the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for
35 ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated

-22-

to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.

5

Those skilled in the art could easily determine the effective amount from the test results presented hereinafter. In general it is contemplated that an effective amount would be from 0.0001 mg/kg to 100 mg/kg body weight, and in particular from 0.001 mg/kg to 10 mg/kg body weight. It may be appropriate to administer the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 0.01 to 500 mg, and in particular 0.1 mg to 200 mg of active ingredient per unit dosage form.

10

Experimental part

15

Hereinafter "THF" means tetrahydrofuran, "DIPE" means diisopropylether, "DCM" means dichloromethane, "DMF" means *N,N*-dimethylformamide and "ACN" means acetonitrile. Of some compounds of formula (I) the absolute stereochemical configuration was not experimentally determined. In those cases the stereochemically isomeric form which was first isolated is designated as "A" and the second as "B", without further reference to the actual stereochemical configuration.

20

A. Preparation of the intermediates

Example A.1

1a) *N*-Phenyl-3-(3-chlorophenyl)-2-propenamide (58.6 g) and polyphosphoric acid (580 g) were stirred at 100°C overnight. The product was used without further purification, yielding quant. (±)-4-(3-chlorophenyl)-3,4-dihydro-2(1*H*)-quinolinone (interm. 1-a).

25

1b) Intermediate (1-a) (58.6 g), 4-chlorobenzoic acid (71.2 g) and polyphosphoric acid (580 g) were stirred at 140°C for 48 hours. The mixture was poured into ice water and filtered off. The precipitate was washed with water, then with a diluted NH₄OH solution and taken up in DCM. The organic layer was dried, filtered off and evaporated. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH/NH₄OH 99/1/0.1). The pure fractions were collected and evaporated, and recrystallized from CH₂Cl₂/CH₃OH/DIPE, yielding 2.2g of (±)-6-(4-chlorobenzoyl)-4-(3-chlorophenyl)-3,4-dihydro-2(1*H*)-quinolinone (interm. 1-b, mp. 194.8°C).

30

35

-23-

1c) Bromine (3.4 ml) in bromobenzene (80 ml) was added dropwise at room temperature to a solution of intermediate (1-b) (26 g) in bromobenzene (250 ml) and the mixture was stirred at 160°C overnight. The mixture was cooled to room temperature and basified with NH₄OH. The mixture was evaporated, the residue was taken up in ACN and filtered off. The precipitate was washed with water and air dried, yielding 24 g (92.7%) of product. A sample was recrystallized from CH₂Cl₂/CH₃OH/DIPE, yielding 2.8 g of 6-(4-chlorobenzoyl)-4-(3-chlorophenyl)-2(1*H*)-quinolinone; mp. 234.8°C (interm. 1-c).

1d) Iodomethane (6.2 ml) was added to a mixture of intermediate (1-c) (20 g) and benzyltriethylammonium chloride (5.7 g) in tetrahydrofuran (200 ml) and sodium hydroxide (10N) (200 ml) and the mixture was stirred at room temperature overnight. ethyl acetate was added and the mixture was decanted. The organic layer was washed with water, dried, filtered off and evaporated till dryness. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH/NH₄OH 99.75/0.25/0.1). The pure fractions were collected and evaporated, yielding 12.3 g (75%) of 6-(4-chlorobenzoyl)-4-(3-chlorophenyl)-1-methyl-2(1*H*)-quinolinone; mp. 154.7°C (interm. 1-d).

In a similar way, but starting from intermediate (1-b), (±)-6-(4-chlorobenzoyl)-4-(3-chlorophenyl)-3,4-dihydro-1-methyl-2(1*H*)-quinolinone (interm 1-e) was prepared.

Example A.2

Butyllithium in hexane (1.6 M) (12.75 ml) was added dropwise at -20°C under N₂ to a solution of 6-bromo-4-(3-chlorophenyl)-2-methoxyquinoline (6.7 g) in THF (60 ml) and the mixture was stirred at -20°C for 30 minutes. A solution of (1-butyl-1*H*-imidazol-5-yl)(4-chlorophenyl)methanone (3.35 g) in tetrahydrofuran (30 ml) was added at -20°C under N₂ and the mixture was stirred at room temperature for one night. Water was added and the mixture was extracted with ethyl acetate. The organic layer was dried, filtered off and evaporated. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH/NH₄OH 97/3/0.1). The pure fractions were collected and evaporated, yielding 2.5 g (total 48%) of (±)-α-(1-butyl-1*H*-imidazol-5-yl)-4-(3-chlorophenyl)-α-(4-chlorophenyl)-2-methoxy-6-quinoline-methanol (interm. 2).

Example A.3

3a) Butyllithium (30.1ml) was added slowly at -78°C to a solution of *N,N*-dimethyl-1*H*-imidazol-1-sulfonamide (8.4 g) in tetrahydrofuran (150 ml) and the mixture was stirred at -78°C for 15 minutes. Chlorotriethylsilane (8.1 ml) was added and the

-24-

mixture was stirred till the temperature reached 20°C. The mixture was cooled till -78°C, butyllithium (30.1 ml) was added, the mixture was stirred at -78°C for 1 hour and allowed to reach -15°C. The mixture was cooled again till -78°C, a solution of 6-(4-chlorobenzoyl)-1-methyl-4-phenyl-2(1*H*)-quinolinone (15 g) in tetrahydrofuran (30 ml) was added and the mixture was stirred till the temperature reached 20°C. The mixture was hydrolyzed and extracted with ethyl acetate. The organic layer was dried, filtered off and evaporated till dryness. The product was used without further purification, yielding 26 g (100%) of (±)-4-[(4-chlorophenyl)(1,2-dihydro-1-methyl-2-oxo-4-phenyl-6-quinolinyl)hydroxymethyl]-*N,N*-dimethyl-2-(triethylsilyl)-1*H*-imidazole-1-sulfonamide (interm. 3-a).

A mixture of intermediate (3-a) (26 g) in sulfuric acid (2.5 ml) and water (250 ml) was stirred and heated at 110°C for 2 hours. The mixture was poured into ice, basified with NH₄OH and extracted with DCM. The organic layer was dried, filtered off and evaporated till dryness. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH/NH₄OH 99/1/0.2). The pure fractions were collected and evaporated, yielding 2.4 g (11%) of (±)-4-[(4-chlorophenyl)(1,2-dihydro-1-methyl-2-oxo-4-phenyl-6-quinolinyl)hydroxymethyl]-*N,N*-dimethyl-1*H*-imidazole-1-sulfonamide (interm. 3-b).

20 Example A.4

Compound (3) (3 g) was added at room temperature to thionyl chloride (25 ml). The mixture was stirred and refluxed at 40°C overnight. The solvent was evaporated till dryness. The product was used without further purification, yielding 3.49 g of (±)-4-(3-chlorophenyl)-1-methyl-6-[1-(4-methylphenyl)-1-(4-methyl-4*H*-pyrrol-3-yl)ethyl]-2(1*H*)-quinolinone hydrochloride (interm. 4).

Example A.5

a) Toluene (1900 ml) was stirred in a round-bottom flask (5 l) using a water separator. (4-Chlorophenyl)(4-nitrophenyl)methanone (250 g) was added portionwise. *p*-Toluene-sulfonic acid (54.5 g) was added portionwise. Ethylene glycol (237.5 g) was poured out into the mixture. The mixture was stirred and refluxed for 48 hours. The solvent was evaporated. The residue was dissolved into ethyl acetate (5 l) and washed twice with a K₂CO₃ 10% solution. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was stirred in DIPE, filtered off and dried (vacuum, 40°C, 24 hours), yielding 265 g (91%) of 2-(4-chlorophenyl)-2-(4-nitrophenyl)-1,3-dioxolane (interm. 5-a).

-25-

- b) Sodium hydroxide (16.4 g) and (3-methoxyphenyl)acetonitrile (20.6 ml) were added at room temperature to a solution of interm. (5-a) (25 g) in methanol (100 ml) and the mixture was stirred at room temperature overnight. Water was added, the precipitate was filtered off, washed with cold methanol and dried. The product was used without further purification, yielding 30 g (90%) of 5-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-3-(3-methoxyphenyl)-2,1-benzisoxazole (interm. 5-b).
- 5 c) Interm. (5-b) (30 g) in THF (250 ml) was hydrogenated with palladium on carbon (3 g) as a catalyst at room temperature for 12 hours under a 2.6×10^5 Pa pressure in a Parr apparatus. After uptake of H_2 (1 equivalent), the catalyst was filtered through celite and the filtrate was evaporated till dryness. The product was used without further purification, yielding 31.2 g (100%) of (3-methoxyphenyl)[2-amino-5-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]phenyl]methanone (interm. 5-c).
- 10 d) Acetic anhydride (13.9 ml) was added to a solution of interm. (5-c) (31.2 g) in toluene (300 ml) and the mixture was stirred and refluxed for 2 hours. The mixture was evaporated till dryness and the product was used without further purification, yielding 36.4 g (100%) of *N*-[2-(3-methoxybenzoyl)-4-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]phenyl]acetamide (interm. 5-d).
- 15 e) Potassium *tert*-butoxide (33 g) was added portionwise at room temperature to a solution of interm. (5-d) (36.4 g) in 1,2-dimethoxyethane (350 ml) and the mixture was stirred at room temperature overnight. The mixture was hydrolyzed and extracted with DCM. The organic layer was dried, filtered off and evaporated till dryness. The product was used without further purification, yielding 43 g of 6-[2-(4-chloro-phenyl)-1,3-dioxolan-2-yl]-4-(3-methoxyphenyl)-2(1*H*)-quinolinone (interm. 5-e).
- 20 f) A mixture of interm. (5-e) (43 g) in HCl (3*N*, 400 ml) and methanol (150 ml) was stirred and refluxed overnight. The mixture was cooled and filtered off. The precipitate was washed with water and diethyl ether and dried. The product was used without further purification, yielding 27 g (94%) of 6-(4-chlorobenzoyl)-4-(3-methoxyphenyl)-2(1*H*)-quinolinone (interm. 5-f).
- 25 g) Methyl iodide (1.58 ml) was added to a solution of interm. (5-f) (7.6 g) and benzyltriethylammonium chloride (BTEAC) (2.23 g) in THF (80 ml) and sodium hydroxide (40%, 80 ml). The mixture was stirred at room temperature for 2 hours. Water was added and the mixture was extracted with ethyl acetate. The organic layer was dried, filtered, and the solvent was evaporated. The residue was purified by flash column chromatography over silica gel (eluent : DCM 100%). The desired fractions were collected and the solvent was evaporated, yielding 7.1 g (90%) of 6-(4-chlorobenzoyl)-4-(3-methoxyphenyl)-1-methyl-2(1*H*)-quinolinone (interm. 5-g).
- 30
- 35

-26-

Example A.6

a) 3-(3-Chlorophenyl)-5-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-2,1-benzisoxazole (interm. 6-a) was prepared analogous as intermediate (5-b).

5 b) A mixture of intermediate (6-a) (30 g) in HCl 3 N (220 ml) and methanol (165 ml) was stirred at 100°C for 5 hours. The mixture was poured into ice and basified with NH₃ (aq.). The precipitate was filtered off, washed with water and diethyl ether and dried, yielding 24.9 g (93%) of (4-chlorophenyl)[3-(3-chlorophenyl)-2,1-benzisoxazol-5-yl]methanone (interm. 6-b). The product was used without further purification.

10 c) Butyllithium in hexanes (10 ml) was added slowly at -70°C under N₂ flow to a solution of 1-methylimidazole (1.31 g) in THF (30 ml). The mixture was stirred at -70°C for 45 minutes. Chlorotriethylsilane (2.7 ml) was added. The mixture was allowed to warm to 15°C and cooled to -70°C. Butyllithium (10 ml) was added slowly. The mixture was stirred at -70°C for 1 hour, allowed to warm to -15°C and cooled to -70°C. A solution of intermediate (6-b) (4.9 g) in THF (60 ml) was added. The mixture
15 was stirred at -70°C for 30 minutes, then hydrolyzed with water, extracted with ethyl acetate and decanted. The organic layer was dried, filtered and the solvent was evaporated. The residue (8.2 g) was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH/NH₄OH 96/4/0.2) and crystallized from 2-propanone/diethyl ether. The precipitate was filtered off and dried, yielding 1.5 g (25%) of (±)-3-(3-chlorophenyl)-α-(4-chlorophenyl)-α-(1-methyl-1*H*-imidazol-5-yl)-2,1-benzisoxazole-5-methanol (interm. 6-c).
20

d) TiCl₃/15% in H₂O (200 ml) was added at room temperature to a solution of intermediate (6-c) (38 g) in THF (300 ml). The mixture was stirred at room temperature for 90 minutes. The mixture was poured out on ice, basified with K₂CO₃, filtered over
25 celite, washed with ethyl acetate and decanted. The organic layer was dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH/NH₄OH 97/3/0.1 and 95/5/0.1), yielding 18.7 g (49%) of (±)-[2-amino-5-[(4-chlorophenyl)hydroxy(1-methyl-1*H*-imidazol-5-yl)methyl]phenyl](3-chlorophenyl)methanone (interm. 6-d).
30

B. Preparation of the final compoundsExample B.1

1-Methylimidazole (4.69 ml) in tetrahydrofuran (100 ml) was stirred at -78°C. A
solution of butyllithium in hexanes (2.5 M) (36.7 ml) was added dropwise and the
35 mixture was stirred at -78°C for 15 minutes. Chlorothiethylsilane (9.87 ml) was added and the mixture was brought to room temperature. The mixture was cooled till -78°C, a solution of butyllithium in hexanes (2.5 M) (36.7 ml) was added dropwise, the mixture

-27-

was stirred at -78°C for 1 hour and brought till -15°C. The mixture was cooled till -78°C, a solution of intermediate (1-d) (20 g) in THF (40 ml) was added and the mixture was brought to room temperature. The mixture was hydrolyzed at 0°C and extracted with ethyl acetate. The organic layer was dried, filtered off and evaporated till dryness, yielding 36 g of product. The product was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH/NH₄OH 97/3/0.1). The pure fractions were collected, evaporated, and crystallized from 2-propanone, CH₃OH and (C₂H₅)₂O. The precipitate was filtered off, washed with (C₂H₅)₂O and dried, yielding 12.4 g (52%) of (±)-4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1*H*-imidazol-5-yl)methyl]-1-methyl-2(1*H*)-quinolinone; (comp. 3, mp.233.6°C).

In a similar way, but using intermediate (5-g) or intermediate (1-e) instead of intermediate (1-d), respectively (±)-6-[(4-chlorophenyl)hydroxy(1-methyl-1*H*-imidazol-5-yl)methyl]-4-(3-methoxyphenyl)-1-methyl-2(1*H*)-quinolinone (comp. 36) and (±)-4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1*H*-imidazol-5-yl)methyl]-3,4-dihydro-1-methyl-2(1*H*)-quinolinone (comp. 127) were prepared.

Example B.2

Hydrochloric acid (60 ml) was added to a solution of intermediate (2) (2.5 g) in THF (10 ml) and the mixture was stirred and heated at 100°C for 3 hours. The mixture was cooled, the precipitate was filtered off, washed with water, then with diethyl ether and dried, yielding 2.7 g (100%) of (±)-6-[(1-butyl-1*H*-imidazol-5-yl)-(4-chlorophenyl)hydroxymethyl]-4-(3-chlorophenyl)-2(1*H*)-quinolinone (comp. 8).

Example B.3

Sodium hydride (0.28 g) was added to a mixture of compound (3) (3 g) in DMF (50 ml) under N₂ and the mixture was stirred for 15 minutes. Iodomethane (1.5 ml) was added and the mixture was stirred at room temperature for 1 hour. The mixture was hydrolyzed and extracted with diethyl ether and methanol. The organic layer was dried, filtered off and evaporated till dryness, yielding 4.4 g of residue. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH/NH₄OH 95.5/4.5/0.2). The pure fractions were collected and evaporated. The product was converted into the ethanedioic acid salt (1:1) in 2-propanone and filtered off. The residue was crystallized from 2-propanone, diethyl ether and DIPE. The precipitate was filtered off, washed with diethyl ether, dried and recrystallized from 2-propanone, methanol and DIPE. The precipitate was filtered off, washed with diethyl ether and dried, yielding 0.95 g (25%) of (±)-4-(3-chlorophenyl)-6-[(4-chlorophenyl)methoxy(1-

-28-

methyl-1*H*-imidazol-5-yl)methyl]-1-methyl-2(1*H*)-quinolinone ethanedioate(1:1).dihydrate; (comp. 4, mp. 154.6°C).

Example B.4

- 5 Iodomethane (0.38 ml) was added dropwise at room temperature to a solution of compound (8) (2.44 g) and *N,N,N*-triethylbenzenemethanaminium chloride (0.54 g) in tetrahydrofuran (30 ml) and sodium hydroxide (40%) (30 ml) and the mixture was stirred at room temperature for 3 hours. Water was added and the mixture was extracted with ethyl acetate. The organic layer was dried, filtered off and evaporated.
- 10 The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH/ NH₄OH 96.5/3.5/0.1). The pure fractions were collected, evaporated and crystallized from 2-propanone and DIPE. The precipitate was filtered off, washed with diethyl ether and dried, yielding 1.4 g (56%) of (±)-4-(3-chlorophenyl)-6-[(1-butyl-1*H*-imidazol-5-yl)(4-chlorophenyl)hydroxymethyl]-1-methyl-2(1*H*)-quinolinone;
- 15 (comp. 9, mp. 174.6°C).

Example B.5

- Iodomethane (1.4 ml) was added to a mixture of (±)-6-[(4-chlorophenyl)-1*H*-imidazol-4-ylmethyl]-1-methyl-4-phenyl-2(1*H*)-quinolinone (7.5 g) and
- 20 benzyltrienylammonium chloride (2 g) in THF (75 ml) and sodium hydroxide (75 ml) and the mixture was stirred at room temperature for 1 hour. Water was added and the mixture was extracted with ethyl acetate. The organic layer was dried, filtered off and evaporated till dryness. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH/NH₄OH 98.5/1.5/0.1). The pure fractions were
- 25 collected and evaporated. Fraction 1 (3.5 g) was recrystallized from diethyl ether, yielding 3.3 g (42%) of (±)-6-[(4-chlorophenyl)(1-methyl-1*H*-imidazol-4-yl)methyl]-1-methyl-4-phenyl-2(1*H*)-quinolinone; mp. 149.9°C (comp. 44). Fraction 2 was recrystallized from 2-propanone, methanol and diethyl ether, yielding 1.6 g (20%) of (±)-6-[(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-1-methyl-4-phenyl-2(1*H*)-
- 30 quinolinone (comp. 2, mp. 96.8°C).

Example B.6

- Sodium borohydride (5.6 g) was added portionwise at 0°C under N₂ to compound (3) (7.2 g) dissolved in trifluoroacetic acid (150 ml) and the mixture was stirred at room
- 35 temperature overnight. The mixture was poured into ice, basified with NaOH 3N, then concentrated NaOH and extracted with ethyl acetate. The organic layer was dried, filtered off and evaporated till dryness. The residue was purified by column

- chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH 95/5). The pure fractions were collected and evaporated, yielding 4.3 g (62%) of fraction 1; 0.2 g (3%) of fraction 2 and 2 g (29%) of fraction 3. Fraction 1 was converted into the ethanedioic acid salt (1:1) in 2-propanone and diethyl ether. The precipitate was filtered off,
 5 washed with diethyl ether and dried, yielding 4.7 g (55%) of (±)-4-(3-chlorophenyl)-6-[(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-1-methyl-2(1*H*)-quinolinone ethanedioate(1:1).mono-hydrate (comp. 5, mp. 157.4°C).

Example B.7

- 10 A solution of compound 90 (4.2 g) in 1,2-dimethoxyethane (70 ml) was stirred under N₂ for 30 minutes. Iodomethane (0.83 ml), followed by potassium *tert*-butoxide (2 g) were added portionwise and the mixture was stirred at room temperature for 30 minutes. Water was added and the mixture was extracted with ethyl acetate. The organic layer was dried, filtered off and evaporated. The residue was purified by
 15 column chromatography over silica gel (eluent : cyclohexane/2-propanol/NH₄OH 85/5/0.5 to 80/20/1) and converted into the ethanedioic acid salt, crystallized from 2-propanone and filtered off, yielding 1.16 g (23.6%) of (±)-4-(3-chlorophenyl)-6-[1-(4-chloro-phenyl)-1-(1-methyl-1*H*-imidazol-5-yl)ethyl]-1-methyl-2(1*H*)-quinolinone.ethanedioate (1:1); (comp. 12, mp. 203.9°C).
 20 In a similar way, but replacing iodomethane by dichloromethane or dibromomethane, respectively (±)-6-[2-chloro-1-(4-chlorophenyl)-1-(1-methyl-1*H*-imidazol-5-yl)ethyl]-4-(3-chlorophenyl)-1-methyl-2(1*H*)-quinolinone ethanedioate (1:1) (comp. 69) and (±)-6-[2-bromo-1-(4-chlorophenyl)-1-(1-methyl-1*H*-imidazol-5-yl)ethyl]-4-(3-chlorophenyl)-1-methyl-2(1*H*)-quinolinone (comp. 70) were prepared.

Example B.8

- a) Compound (3) (3 g) was separated (into its enantiomers) and purified by high-performance liquid chromatography over Chiracel OD (20 µm; eluent : hexane/ethanol 50/50). The pure (A)-fractions were collected, and the solvent was
 30 evaporated, yielding 1.6 g ((A); LCI: > 99%). The pure (B)-fractions were collected, and the solvent was evaporated, yielding 1.5 g ((B); LCI: > 99%). The (A)-residue was dissolved in 2-propanol and converted into the ethanedioic acid salt (1:1). The precipitate was filtered off and dried, yielding 0.6 g (17%) of (+)-4-(3-chlorophenyl)-6-[(4-chloro-phenyl)-hydroxy(1-methyl-1*H*-imidazol-5-yl)methyl]-1-methyl-2(1*H*)-
 35 quinolinone ethanedioate (1:1) ; $[\alpha]_D^{20} = +17.96^\circ$ (c = 1% in methanol) (comp. 23). The (B)-residue was dissolved in 2-propanol and converted into the ethanedioic acid salt (1:1). The precipitate was filtered off and dried, yielding 0.6 g (17%) (-)-4-(3-

-30-

chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1*H*-imidazol-5-yl)methyl]-1-methyl-2(1*H*)-quinolinone ethanedioate(1:1); $[\alpha]_D^{20} = -18.87^\circ$ (c = 1% (w/v) in methanol) (comp. 24).

b) Compound 14 (4 g) was separated (into its enantiomers) and purified by chiral column chromatography over Chiralcel OD (25 cm; eluent : 100% ethanol; flow: 0.5 ml/min; wavelength : 220 nm). The pure (A)-fractions were collected, and the solvent was evaporated. This residue was dissolved in DCM (100 ml), filtered, and the filtrate was evaporated. The residue was stirred in DIPE (100 ml), filtered off and dried, yielding 1.3 g (-)-6-[amino(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-4-(3-chloro-phenyl)-1-methyl-2(1*H*)-quinolinone ($[\alpha]_D^{20} = -6.16^\circ$ (c = 0.67 % (w/v) in methanol)(comp. 74).

The pure (B)-fractions were collected and evaporated. The residue was crystallized from 2-propanol. The precipitate was filtered off, yielding 1.3 g (+)-6-[amino(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1*H*)-quinolinone ($[\alpha]_D^{20} = +22.86^\circ$ (c = 0.98 % (w/v) in methanol) (comp. 75).

Example B.9

Air was bubbled through a solution of compound (47) (3.6 g) in THF (40 ml) for 30 minutes. 2-Methyl-2-propanol potassium salt (4.4 g) was added. The mixture was stirred at room temperature for 3 hours, hydrolyzed and then extracted with DCM. The organic layer was separated, dried, filtered and the solvent was evaporated, yielding 2.9 g of product. The product was purified by column chromatography over silica gel (eluent : CH₂Cl₂/ CH₃OH/NH₄OH 97.5/2.5/0.1). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from 2-propanone / DIPE. The precipitate was filtered off and dried, yielding 1.3 g (35%) of (±)-4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1*H*-imidazol-4-yl)methyl]-1-methyl-2(1*H*)-quinolinone (comp. 48).

Example B.10

A mixture of (±)-4-[(4-chlorophenyl)(1,2-dihydro-1-methyl-2-oxo-4-phenyl-6-quinolinyl)hydroxymethyl]-*N,N*-dimethyl-1*H*-imidazole-1-sulfonamide (2.4 g) in hydrochloric acid (10 ml), water (30 ml) and methanol (15 ml) was stirred and heated at 110°C for 14 hours. The mixture was cooled, basified with NH₃ (aq.) and extracted with DCM. The organic layer was dried, filtered off and evaporated till dryness. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH/NH₄OH 95/5/0.2). The pure fractions were collected and evaporated. The residue (1.25 g) was crystallized from 2-propanone/ DIPE, yielding 1 g (48.3%) of

-31-

(±)-6-[(4-chlorophenyl)hydroxy(1*H*-imidazol-4-yl)methyl]-1-methyl-4-phenyl-2(1*H*)-quinolinone monohydrate (comp. 43).

Example B.11

- 5 Compound (3) (4 g) was dissolved in DCM (10 ml) and acetic acid (5.6 ml) at 45°C. Zinc chloride (5.5 g), followed by cyanoacetic acid (3.5 g) were added. The mixture was stirred at 120°C for 3 hours and then at 160°C for 10 hours. Water was added and the mixture was extracted with DCM. The organic layer was washed with K₂CO₃ 10%, dried, filtered, and the solvent was evaporated. The residue was purified by
10 column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH/NH₄OH 96/4/0.2), crystallized from 2-propanone/ DIPE, filtered off and dried, yielding 1.95 g (45%) of (±)-4-(3-chlorophenyl)-β-(4-chlorophenyl)-1,2-dihydro-1-methyl-β-(1-methyl-1*H*-imidazol-5-yl)-2-oxo-6-quinolinepropanenitrile; (comp. 25, mp. 151.3°C).

15 Example B.12

- Sulfuric acid (1 ml) was added dropwise to acetonitrile (30 ml), while stirring. Compound 3 (3 g) was added. The mixture was stirred at 80°C for 3 hours and then cooled. K₂CO₃ 10% was added and the mixture was extracted with ethyl acetate. The organic layer was separated, dried, filtered and the solvent was evaporated till dryness.
20 The residue (3.58 g) was dissolved in 2-propanone and converted into the ethanedioic acid salt (1:1). The precipitate was filtered off, dried and crystallized from 2-propanone/CH₃OH. The precipitate was filtered off and dried, yielding 3.5 g (92%) of (±)-*N*-[(4-chlorophenyl)[4-(3-chlorophenyl)-1,2-dihydro-1-methyl-2-oxo-6-quinolinyl](1-methyl-1*H*-imidazol-5-yl)methyl]acetamide ethanedioate (1:1)
25 (comp. 56).

Example B.13

- NH₃ (aq.) (40 ml) was added at room temperature to a mixture of intermediate 4 (7 g) in THF (40 ml). The mixture was stirred at 80°C for 1 hour, then hydrolyzed and
30 extracted with DCM. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent : toluene/2-propanol/NH₄OH 80/20/1). The pure fractions were collected and the solvent was evaporated, yielding 4.4 g(±)-6-[amino(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1*H*)-quinolinone (comp. 14).
35

Example B.14

A solution of compound 36 (6.2 g) in DCM (140 ml) was cooled and tribromoborane (32 ml) was added dropwise. The mixture was stirred at room temperature for the days.

-32-

The mixture was poured out into ice water, basified with NH_3 (aq.) and extracted with $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$. The organic layer was separated, dried, filtered and the solvent was evaporated till dryness, yielding 6 g (100%) of (\pm)-6-[(4-chlorophenyl)-hydroxy-(1-methyl-1*H*-imidazol-5-yl)methyl]-4-(3-hydroxyphenyl)-1-methyl-2(1*H*)-quinolinone (comp. 54).

Example B.15

A mixture of compound 54 (2.5 g), 2-chloro-*N,N*-dimethyl-ethanamine (1.9 g) and potassium carbonate (2.2 g) in ACN (50 ml) and DMF (50 ml) was stirred at 100°C overnight. The solvent was evaporated till dryness. The residue was taken up in CH_2Cl_2 /water and decanted. The organic layer was dried, filtered and the solvent was evaporated. The residue (2.7 g) was purified by column chromatography over silica gel (eluent : $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$ 97/3/0.1 to 90/10/0.1). The pure fractions were collected and the solvent was evaporated. The residue was converted into the ethanedioic acid salt (1:1) in 2-propanone. The precipitate was filtered off, washed with 2-propanone / diethyl ether and dried. The residue was converted into the free base. The precipitate was filtered off and dried. The residue was crystallized from diethyl ether. The precipitate was filtered off and dried, yielding 0.35 g (12%) of (\pm)-6-[(4-chloro-phenyl)hydroxy(1-methyl-1*H*-imidazol-5-yl)methyl]-4-[3-[2-(dimethylamino)ethoxy]-phenyl]-1-methyl-2(1*H*)-quinolinone (comp. 62).

Example B.16

P_4S_{10} (12 g) was added to a mixture of compound 90 (6 g) in pyridine (72 ml). The mixture was stirred and refluxed for 6 hours. Ice water was added. The precipitate was filtered off, washed with water and taken up in DCM. The organic layer was separated, dried, filtered and the solvent was evaporated till dryness. The residue was purified by column chromatography over silica gel (eluent : $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$ 97.5/2.5/0.1). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from 2-propanone/diethyl ether. The precipitate was filtered off and dried, yielding 1 g of (\pm)-4-(3-chlorophenyl)-6-[(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-1-methyl-2(1*H*)-quinolinethione (comp. 128).

Example B.17

A mixture of ethyl malonyl chloride (6.4 ml) in DCM (50 ml) was added dropwise at room temperature to a solution of intermediate (6-d) (15 g) and pyridine (10.7 ml) in DCM (150 ml). The mixture was stirred at room temperature overnight. Water was added and the mixture was decanted. The organic layer was dried, filtered and the

solvent was evaporated. The residue (21 g) was purified by column chromatography over silica gel (eluent : CH₂Cl₂/2-propanol/NH₄OH 92/8/0.4). The desired fractions were collected and the solvent was evaporated, yielding 10.9 g (60%) of (±)-ethyl 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1*H*-imidazol-5-yl)methyl]-1,2-dihydro-2-oxo-3-quinolinecarboxylate (comp. 144).

Example B.18

- a) A mixture of benzoyl chloride (3.1 ml) in DCM (25 ml) was added dropwise at room temperature to a solution of interm. (6-d) (7 g) and pyridine (5 ml) in DCM (70 ml). The mixture was stirred at room temperature for 45 minutes. Water was added and the mixture was decanted. The organic layer was dried, filtered and the solvent was evaporated, yielding 8.8 g of (±)-*N*-[2-(3-chlorobenzoyl)-4-[(4-chlorophenyl)hydroxy(1-methyl-1*H*-imidazol-5-yl)methyl]phenyl]benzeneacetamide (interm. 7). The product was used without further purification.
- b) Potassium *tert*-butoxide (8.7 g) was added to a mixture of intermediate 7 (8.8 g) in DME (70 ml). The mixture was stirred at 50°C for 3 hours. Water (5 ml) was added and the solvent was evaporated, yielding 8.5 g of (±)-4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1*H*-imidazol-5-yl)methyl]-3-phenyl-2(1*H*)-quinolinone (comp. 140).

Example B.19

- NH₃ (aq.) (150 ml) was cooled to 5°C. A solution of (±)-4-(3-chlorophenyl)-1-methyl-6-[1-(4-methylphenyl)-1-(4-methyl-4*H*-pyrrol-3-yl)ethyl]-2(1*H*)-quinolinone hydrochloride (16.68 g) in THF (150 ml) was added. The mixture was stirred at room temperature for 2 hours, decanted and extracted with ethyl acetate. The organic layer was dried, filtered and the solvent was evaporated till dryness. The reaction was carried out twice. The residues were combined and purified by column chromatography over silica gel (eluent : toluene/2-propanol/NH₄OH 70-29-1). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from CH₂Cl₂/CH₃OH/CH₃CN. The precipitate was filtered off and the mother layer was evaporated till dryness, purified by column chromatography (eluent : CH₃OH/NH₄OAc (0.5% in H₂O) 70/30). Two pure fractions were collected and their solvents were evaporated till dryness. Fraction 2 was recrystallized from CH₂Cl₂/diethyl ether. The precipitate was filtered off and dried, yielding 0.8 g of (±)-6-[amino(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-3-chloro-4-(3-chlorophenyl)-1-methyl-2(1*H*)-quinolinone (comp. 143).


Example B.20

Sulfuric acid (1 ml) was added at room temperature to a solution of compound 3 (3.5 g) in methoxyacetonitrile (10 ml) and the mixture was stirred and heated at 80°C for 3 hours. The mixture was cooled, poured into ice, basified with NH₃ (aq.) and filtered off. The precipitate was taken up in DCM. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH/NH₄OH 96/4/0.3). The pure fractions were collected and the solvent was evaporated. The residue was converted into the hydrochloric acid salt (1:1) and crystallized from ACN. The precipitate was filtered off and dried, yielding 2.5 g (58%) of (±)-*N*-[(4-chlorophenyl)[4-(3-chlorophenyl)-1,2-dihydro-1-methyl-2-oxo-6-quinoliny](1-methyl-1*H*-imidazol-5-yl)methyl]-2-methoxyacetamide monohydrochloride (comp. 89).

Example B.21

A solution of intermediate (4) (3.3 g) in THF (10 ml) was added dropwise at room temperature to a solution of methanamine in water (40 ml). The mixture was stirred at 80°C for 45 minutes, taken up in water and extracted with DCM. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH/NH₄OH 97/3/0.3 and 95/5/0.3). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from diethyl ether. The precipitate was filtered off and dried, yielding 0.89 g (28%) of (±)-4-(3-chlorophenyl)-6-[(4-chloro-phenyl)(methylamino)-(1-methyl-1*H*-imidazol-5-yl)methyl]-1-methyl-2(1*H*)-quinolinone monohydrate (comp. 61).

Tables 1 to 8 list the compounds that were prepared according to one of the above Examples and table 9 lists both the experimental (column heading "exp.") and theoretical (column heading "theor.") elemental analysis values for carbon, hydrogen and nitrogen of the compounds as prepared in the experimental part hereinabove.

Table 1 :

Co. No.	Ex. No.	R ¹	R ^{4a}	R ⁸	Physical data
3	B.1	CH ₃	CH ₃	OH	mp. 233.6°C
4	B.3	CH ₃	CH ₃	OCH ₃	mp. 140-160°C; .C ₂ H ₂ O ₄ .H ₂ O
5	B.6	CH ₃	CH ₃	H	mp. 165°C; .C ₂ H ₂ O ₄ .H ₂ O
6	B.5	CH ₃	CH ₂ CH ₃	H	mp. 180°C; .C ₂ H ₂ O ₄ .1/2H ₂ O
7	B.2	H	CH ₃	H	mp. 260°C
8	B.2	H	(CH ₂) ₃ CH ₃	OH	-
9	B.4	CH ₃	(CH ₂) ₃ CH ₃	OH	mp. 174°C
10	B.3	H	CH ₃	OCH ₂ COOCH ₂ CH ₃	mp. 185°C; .3/2C ₂ H ₂ O ₄
11	B.3	CH ₃	CH ₃	O(CH ₂) ₂ N(CH ₃) ₂	mp. 120°C
12	B.7	CH ₃	CH ₃	CH ₃	mp. 210°C; .C ₂ H ₂ O ₄
13	B.7	CH ₃	CH ₃	CH ₂ CH ₃	mp. 196°C; .C ₂ H ₂ O ₄
14	B.13	CH ₃	CH ₃	NH ₂	mp. 220°C
72	B.13	CH ₃	CH ₃	NH ₂	.3/2-(E)-C ₄ H ₄ O ₄
73	B.13	CH ₃	CH ₃	NH ₂	.2HCl
74	B.8b	CH ₃	CH ₃	NH ₂	(-)-
75	B.8b	CH ₃	CH ₃	NH ₂	(+)-; mp. 232.4°C
15	B.3	CH ₃	CH ₃	O(CH ₂) ₃ OH	mp. 135°C
16	B.3	CH ₃	CH ₃	O(CH ₂) ₂ CH ₃	mp. 180°C; .C ₂ H ₂ O ₄ .3/2(H ₂ O)
17	B.3	CH ₃	CH ₃	O(CH ₂) ₂ O-C ₆ H ₅	mp. 144°C; .3/2(C ₂ H ₂ O ₄)
18	B.2	H	CH(CH ₃) ₂	OH	-
19	B.4	CH ₃	CH(CH ₃) ₂	OH	mp. 254°C
20	B.2	H	(CH ₂) ₂ OCH ₃	OH	mp. 112°C
21	B.4	CH ₃	(CH ₂) ₂ OCH ₃	OH	mp. 192°C
22	B.3	CH ₃	CH ₃	O(CH ₂) ₂ OH	mp. 198°C
23	B.8a	CH ₃	CH ₃	OH	mp. 150-200°C; (+)-; .C ₂ H ₂ O ₄
24	B.8a	CH ₃	CH ₃	OH	mp. 150-200°C; (-)-; .C ₂ H ₂ O ₄
25	B.11	CH ₃	CH ₃	CH ₂ -CN	mp. 154°C
27	B.2	H	(CH ₂) ₃ OCH ₃	OH	-

Co. No.	Ex. No.	R ¹	R ^{4a}	R ⁸	Physical data
28	B.4	CH ₃	(CH ₂) ₃ OCH ₃	OH	mp. 196°C; .H ₂ O
29	B.3	CH ₃	CH ₃	O(CH ₂) ₃ OCH ₂ CH ₃	mp. 105°C; .3/2(H ₂ O)
31	B.2	H	CH ₃	OH	> 260°C
32	B.6	CH ₃	(CH ₂) ₂ OCH ₃	H	mp. 140°C; .3/2(C ₂ H ₂ O ₄)
33	B.6	CH ₃	(CH ₂) ₃ OCH ₃	H	mp. 180°C; .HCl
56	B.12	CH ₃	CH ₃	-NHCOCH ₃	.C ₂ H ₂ O ₄
58	B.11	CH ₃	CH ₃	-CH ₂ COOCH ₂ CH ₃	.C ₂ H ₂ O ₄ .3/2(H ₂ O)
60	B.11	CH ₃	CH ₃	1-imidazolyl	-
61	B.21	CH ₃	CH ₃	-NH-CH ₃	mp. 164°C
65	B.2	H	(CH ₂) ₃ SOCH ₃	OH	.H ₂ O
66	B.13	CH ₃	CH ₃	-N(CH ₃) ₂	.2C ₂ H ₂ O ₄ .H ₂ O mp. 160°C
67	B.13	CH ₃	CH ₃	-NH-(CH ₂) ₂ OCH ₃	mp. 216°C
68	B.13	CH ₃	CH ₃	-NH-(CH ₂) ₂ -OH	-
69	B.7	CH ₃	CH ₃	-CH ₂ Cl	.2C ₂ H ₂ O ₄ mp. 220°C
70	B.7	CH ₃	CH ₃	-CH ₂ Br	-
71	*	CH ₃	CH ₃	-CH ₂ OH	.2C ₂ H ₂ O ₄
76	B.4	-(CH ₂) ₂ OCH ₃	CH ₃	OH	mp. 150°C
77	*	CH ₃	CH ₃	-CH ₂ OCH ₃	.2C ₂ H ₂ O ₄ mp. 166°C
78	B.13	CH ₃	CH ₃	-NH-OCH ₃	mp. 170°C
79	B.20	CH ₃	CH ₃	-NH-CONH ₂	.2H ₂ O
80	**	CH ₃	CH ₃	-CH ₂ CONH ₂	-
81	B.13	CH ₃	CH ₃	-NH-OH	-
82	B.13	CH ₃	CH ₃	-NH(CH ₂) ₂ N(CH ₃) ₂	-
83	B.4	(CH ₂) ₂ N(CH ₃) ₂	CH ₃	OH	.3/2C ₂ H ₂ O ₄ .3/2H ₂ O mp. 200 °C
84	*	CH ₃	CH ₃	-CH ₂ N(CH ₃) ₂	.C ₂ H ₂ O ₄ mp. 210°C
85	B.4	CH ₃	CH ₃	-N(CH ₃) ₂	-
86	B.4	CH ₃	CH ₃	NHCOCH ₂ N(CH ₃) ₂	-
87	B.4	CH ₃	CH ₃	-NH(CH ₂) ₉ CH ₃	-


-37-

Co. No.	Ex. No.	R ¹	R ^{4a}	R ⁸	Physical data
88	B.4	CH ₃	CH ₃	-NH(CH ₂) ₂ NH ₂	-
89	B.20	CH ₃	CH ₃	-NHCOCH ₂ OCH ₃	.HCl mp. 220°C
90	B.6	CH ₃	CH ₃	H	-
91	B.20	CH ₃	CH ₃	-NHCOCH ₂ C ₆ H ₅	.C ₂ H ₂ O ₄ .H ₂ O mp. 170°C
92	B.20	CH ₃	CH ₃	-NHCOC ₆ H ₅	mp. 242°C
93	B.20	CH ₃	CH ₃	-NHCOCONH ₂	.C ₂ H ₂ O ₄ .H ₂ O mp. 186°C
94	B.13	CH ₃	CH ₃	-NHC ₆ H ₅	mp. 165°C

* : prepared by functional-group transformation of compound 70

** : prepared by functional-group transformation of compound 25

Table 2:



5

Co. No.	Ex. No.	R ¹	R ²	R ^{4a}	R ⁵	R ⁸	Physical data
1	B.1	CH ₃	H	CH ₃	H	OH	mp. >250°C
2	B.5	CH ₃	H	CH ₃	H	H	mp. 100-110°C
26	B.1	CH ₃	3-Cl	CH ₃	2-CH ₃	OH	mp. 200°C
30	B.6	CH ₃	3-Cl	CH ₃	2-CH ₃	H	mp. 120-140°C; .3/2(C ₂ H ₂ O ₄).H ₂ O
34	B.1	CH ₃	3-O-CH ₂ -CH ₃	CH ₃	H	OH	mp. 190°C
35	B.6	CH ₃	3-O-CH ₂ -CH ₃	CH ₃	H	H	mp. 160-180°C; .HCl.H ₂ O
36	B.1	CH ₃	3-O-CH ₃	CH ₃	H	OH	mp. 210°C
37	B.1	CH ₃	3-O-(CH ₂) ₂ -CH ₃	CH ₃	H	OH	mp. 150-160°C
38	B.1	CH ₃	3-O-(CH ₂) ₃ -CH ₃	CH ₃	H	OH	mp. 150-160°C
49	B.1	CH ₃	4-O-CH ₂ -CH ₃	CH ₃	H	OH	mp. 184.2°C
50	B.1	CH ₃	3-O-CH-(CH ₃) ₂	CH ₃	H	OH	mp. 147.1°C

Co. No.	Ex. No.	R ¹	R ²	R ^{4a}	R ⁵	R ⁸	Physical data
51	B.6	CH ₃	3-O-(CH ₂) ₃ -CH ₃	CH ₃	H	H	mp. 164.2°C; .3/2(C ₂ H ₂ O ₄)
52	B.6	CH ₃	3-O-(CH ₂) ₂ -CH ₃	CH ₃	H	H	.3/2(C ₂ H ₂ O ₄)
53	B.6	CH ₃	3-O-CH-(CH ₃) ₂	CH ₃	H	H	mp. 133.9°C; .C ₂ H ₂ O ₄ .H ₂ O
54	B.14	CH ₃	3-OH	CH ₃	H	OH	-
64	B.10	CH ₃	3-OH	CH ₃	H	OH	.HCl.H ₂ O
55	B.6	CH ₃	3-OH	CH ₃	H	H	mp. >250°C
57	B.1	CH ₃	2-OCH ₂ CH ₃	CH ₃	H	OH	-
59	B.13	CH ₃	3-OCH ₂ CH ₃	CH ₃	H	NH ₂	-
95	B.8a	CH ₃	3-OCH ₂ CH ₃	CH ₃	H	NH ₂	(A)
96	B.8a	CH ₃	3-OCH ₂ CH ₃	CH ₃	H	NH ₂	(B)
62	B.15	CH ₃	3-O(CH ₂) ₂ N(CH ₃) ₂	CH ₃	H	OH	-
63	B.11	CH ₃	3-O(CH ₂) ₂ -OH	CH ₃	H	OH	-
97	B.1	CH ₃	3-CH ₂ CH ₃	CH ₃	H	OH	-
98	B.13	CH ₃	3-CH ₂ CH ₃	CH ₃	H	NH ₂	mp. 240°C
99	B.1	CH ₃	3-(CH ₂) ₂ CH ₃	CH ₃	H	OH	-
100	B.13	CH ₃	3-(CH ₂) ₂ CH ₃	CH ₃	H	NH ₂	-
101	*	CH ₃	3-O-(CH ₂) ₂ OCH ₃	CH ₃	H	OH	.3/2(C ₂ H ₂ O ₄) mp. 193°C
102	B.1	CH ₃	3-CH ₃	CH ₃	H	OH	mp. >250°C
103	B.13	CH ₃	3-CH ₃	CH ₃	H	NH ₂	-
104	B.1	CH ₃	3-Br	CH ₃	H	OH	-
105	B.13	CH ₃	3-Br	CH ₃	H	NH ₂	-
106	B.1	CH ₃	3-O-CF ₃	CH ₃	H	OH	-
107	B.13	CH ₃	3-O-CF ₃	CH ₃	H	NH ₂	mp. 168°C
108	B.1	CH ₃	3-C ₆ H ₅	CH ₃	H	OH	-
109	B.13	CH ₃	3-C ₆ H ₅	CH ₃	H	NH ₂	-
110	B.1	CH ₃	3-F	CH ₃	H	OH	-
111	B.13	CH ₃	3-F	CH ₃	H	NH ₂	mp. >250°C
112	B.1	CH ₃	3-(E)-CH=CH-CH ₃	CH ₃	H	OH	mp. >250°C
113	B.2	H	3-Cl	CH ₃	3-Cl	OH	-
114	B.4	CH ₃	3-Cl	CH ₃	3-Cl	OH	-
115	B.1	CH ₃	3-Cl	H	3-CH ₃	OH	-
116	B.4	CH ₃	3-Cl	CH ₃	3-CH ₃	OH	-
117	**	CH ₃	3-CN	CH ₃	H	OH	-

-39-


Co. No.	Ex. No.	R ¹	R ²	R ^{4a}	R ⁵	R ⁸	Physical data
160	B.1	CH ₃	3-CF ₃	CH ₃	H	OH	-

* : prepared by functional-group transformation of compound 54

** : prepared by functional-group transformation of compound 104


Table 3 :

5



Co. No.	Ex. No.	R ¹	R ⁸	Physical data
39	B.4	CH ₂ CONHCH(COOCH ₃)(CH ₂ CH(CH ₃) ₂)	H	mp. 240°C (S)
40	B.4	CH ₂ -2-quinolinyl	H	mp. 240°C; .2 HCl
41	B.4	CH ₂ CONHCH(COOCH ₃)(CH ₂ CH(CH ₃) ₂)	OH	mp. > 260°C (S)

Table 4 :




10

Co. No.	Ex. No.	R ²	R ⁴	R ^{5a}	R ⁶	R ⁸	Physical data
42	B.6	H	H	H	4-Cl	H	mp. 170°C; .C ₂ H ₂ O ₄ .1/2 H ₂ O
43	B.10	H	H	H	4-Cl	OH	mp. 180°C; .H ₂ O
44	B.5	H	H	CH ₃	4-Cl	H	mp. 152°C
45	B.6	3-Cl	H	H	4-Cl	H	mp. 175°C; .C ₂ H ₂ O ₄
46	B.5	3-Cl	H	CH ₂ CH ₃	4-Cl	H	mp. 132°C; .C ₂ H ₂ O ₄
47	B.5	3-Cl	H	CH ₃	4-Cl	H	mp. 115°C; .3/2 C ₂ H ₂ O ₄

-40-

Co. No.	Ex. No.	R ²	R ⁴	R ^{5a}	R ⁶	R ⁸	Physical data
48	B.9	3-Cl	H	CH ₃	4-Cl	OH	mp. 230°C
118	B.4	3-Cl	3-CH ₃	CH ₃	4-Cl	OH	mp. 222°C


Table 5 :



Co. No.	Ex. No.	-R ² -R ³ -	R ⁶	R ⁸
119	B.1	-O-CH ₂ -O-	4-Cl	OH
120	B.13	-O-CH ₂ -O-	4-Cl	NH ₂
121	B.1	-O-CH ₂ -CH ₂ -O-	4-Cl	OH
122	B.13	-O-CH ₂ -CH ₂ -O-	4-Cl	NH ₂
123	B.1	-O-CH=CH-	4-Cl	OH

5


Table 6 :



Co. No.	Ex. No.	X	-----	R ²	R ³	R ¹⁶	R ⁸	Physical data
124	B.1	O	double	3-OCH ₃	4-OCH ₃	5-OCH ₃	OH	mp. 230°C
125	B.13	O	double	3-OCH ₃	4-OCH ₃	5-OCH ₃	NH ₂	mp. 218°C
126	B.1	O	single	3-Cl	H	H	OH	.C ₂ H ₂ O ₄ mp. 160°C
127	B.1	O	single	3-Cl	H	H	OH	-
128	B.16	S	double	3-Cl	H	H	H	-


-41-

Table 7:



Co. No.	Ex. No.	R ¹	R ¹⁷	R ¹⁸	R ¹⁹	R ⁸	Physical data
129	B.17	H	CN	H	H	H	-
130	B.4	CH ₃	CN	H	H	H	mp. 202°C
131	B.17	H	CN	H	H	OH	-
132	B.4	CH ₃	CN	H	H	OH	-
133	B.17	H	CN	H	H	-CH ₂ CN	-
134	B.4	CH ₃	CN	H	H	-CH ₂ CN	mp. 138°C
135	B.18	H	CH ₃	H	H	OH	-
136	B.4	CH ₃	CH ₃	H	H	OH	-
137	B.13	CH ₃	CH ₃	H	H	NH ₂	mp. >250°C
138	B.18	H	C ₆ H ₅	H	H	H	-
139	B.4	CH ₃	C ₆ H ₅	H	H	H	.3/2(C ₂ H ₂ O ₄) mp. 180°C
140	B.18	H	C ₆ H ₅	H	H	OH	-
141	B.4	CH ₃	C ₆ H ₅	H	H	OH	-
142	B.13	CH ₃	C ₆ H ₅	H	H	NH ₂	-
143	B.13	CH ₃	Cl	H	H	NH ₂	-
144	B.17	H	-COOCH ₂ CH ₃	H	H	OH	-
145	B.4	CH ₃	-COOCH ₂ CH ₃	H	H	OH	-
146	B.1	CH ₃	H	8-CH ₃	H	OH	-
147	B.13	CH ₃	H	8-CH ₃	H	NH ₂	.H ₂ O
148	B.1	CH ₃	H	7-Cl	H	OH	-
149	B.1	CH ₃	H	7-CH ₃	H	OH	-
150	B.1	CH ₃	H	5-CH ₃	H	OH	-
151	B.1	CH ₃	H	8-OCH ₃	H	OH	-
161	B.1	CH ₃	H	7-CH ₃	8-CH ₃	OH	mp. 255°C

Table 8 :



Co. No.	Ex. No.	R ²	R ³	R ⁶	R ⁷	R ⁸	Physical data
152	B.1	3-OCH ₂ CH ₃	H	4-OCH ₂ CH ₃	H	OH	.3/2(C ₂ H ₂ O ₄)
153	B.1	3-Cl	H	H	H	OH	-
154	B.1	3-Cl	H	4-CH ₃	H	OH	-
155	B.1	3-Cl	H	4-OCH ₃	H	OH	-
156	B.1	3-Cl	H	4-CF ₃	H	OH	-
157	B.1	3-Cl	H	2-Cl	4-Cl	OH	-
158	B.1	3-Cl	5-Cl	4-Cl	H	OH	-
159	B.1		H	4-Cl	H	OH	-
162	B.1	3-Cl	H	4-S-CH ₃	H	OH	mp. 169°C .C ₂ H ₂ O ₄ .H ₂ O;
163	B.1	3-Cl	H	4-N(CH ₃) ₂	H	OH	mp.decomposes > 172°C
164	B.1	3-Cl	H	-CH=CH-CH=CH- *		OH	.C ₂ H ₂ O ₄

5 * : R⁶ and R⁷ taken together to form a bivalent radical between positions 3 and 4 on the phenyl moiety

Table 9 :

Comp. No.	Carbon		Hydrogen		Nitrogen	
	Exp.	Theor.	Exp.	Theor.	Exp.	Theor.
57	67.78	69.66	4.82	5.24	7.83	8.40
58	58.59	58.50	4.58	4.76	5.96	6.20
59	69.68	69.80	5.38	5.45	11.06	11.23
60	65.89	66.67	4.35	4.29	11.30	12.96
62	66.51	68.56	5.74	5.75	9.67	10.32

Comp. No.	Carbon		Hydrogen		Nitrogen	
	Exp.	Theor.	Exp.	Theor.	Exp.	Theor.
63	66.64	67.50	5.29	5.08	7.63	8.14
64	62.20	61.60	4.70	4.79	7.97	7.98
65	58.90	59.59	4.42	4.66	6.79	7.19
68	64.29	65.29	4.87	4.91	10.13	10.50
71	60.68	60.62	3.86	4.24	6.87	7.07
73	54.33	57.67	4.51	4.30	9.26	9.96
74	66.64	66.26	4.28	4.53	11.33	11.45
75	66.26	66.26	4.39	4.53	11.30	11.45
79	59.89	59.16	4.65	4.79	12.18	12.32
80	64.27	65.54	4.71	4.55	10.36	10.54
81	64.27	64.17	4.44	4.39	10.92	11.09
82	65.98	66.43	5.88	5.57	11.61	12.49
85	66.20	67.31	5.22	5.06	10.44	10.83
86	64.83	64.81	4.96	5.09	12.12	12.19
87	69.63	70.58	6.88	6.72	8.70	8.90
88	65.21	65.42	5.10	5.11	13.22	13.15
97	71.38	71.97	5.60	5.41	8.17	8.68
98	71.38	72.11	5.58	5.63	11.31	11.60
100	71.92	72.50	5.65	5.88	10.92	11.27
103	70.72	71.71	5.42	5.37	11.80	11.95
104	60.56	60.63	3.99	3.96	7.84	7.86
105	60.33	60.75	3.72	4.15	10.28	10.49
106	62.37	62.29	3.71	3.92	7.71	7.78
108	74.22	74.50	4.94	4.93	7.83	7.90
109	74.17	74.64	5.23	5.12	10.60	10.55
110	68.17	68.43	4.28	4.47	8.75	8.87
115	65.98	66.13	4.08	4.32	8.53	8.57
116	66.49	66.67	4.38	4.60	8.47	8.33
117	67.97	69.93	4.60	4.40	11.14	11.65
120	67.35	67.40	4.62	4.65	11.14	11.23
121	67.32	67.77	4.72	4.71	7.78	8.18
122	67.88	67.90	4.72	4.91	10.88	10.92
123	69.75	70.23	4.77	4.47	8.06	8.47
128	65.88	66.12	4.24	4.32	8.37	8.57
132	65.20	65.25	3.77	3.91	10.42	10.87

Comp.	Carbon		Hydrogen		Nitrogen	
No.	Exp.	Theor.	Exp.	Theor.	Exp.	Theor.
136	66.77	66.67	4.64	4.60	8.34	8.33
142	69.26	70.09	4.42	4.63	9.59	9.91
145	64.36	64.06	4.19	4.48	7.49	7.47
148	61.88	61.79	3.65	3.84	7.88	8.01
150	66.56	66.67	4.64	4.60	8.08	8.33
151	64.76	64.62	4.86	4.45	7.80	8.07
153	70.99	71.13	5.17	4.86	9.25	9.22
154	71.67	71.56	5.08	5.15	9.14	8.94
158	61.72	61.79	3.76	3.84	7.96	8.01
159	69.28	69.50	5.21	5.29	10.01	10.13
160	62.71	64.19	3.91	4.04	7.36	8.02

C. Pharmacological Example

C.1. Inhibition of smooth muscle cell proliferation.


The effects of the compounds of the present invention were studied in human
 5 pulmonary artery smooth muscle cells (PASMC), human coronary artery smooth
 muscle cells (CASMC), and rat A10 arterial smooth muscle cells growing under
 standard tissue culture conditions. CASMC and PASMC cell cultures were purchased
 from Clonetics (San Diego, CA). A10 smooth muscle cells were purchased from the
 American Type Culture Collection (Bethesda, MD). Cells were inoculated at an initial
 10 cell density of 50,000 cells per well in six-well plastic cluster tissue culture dishes in
 3.0 ml of complete growth medium. Test compounds were dissolved in
 dimethylsulfoxide (DMSO) and added in a 3 μ l volume to each well to produce the
 desired concentrations of said test compound (5, 10, 50, 100 and 500 nM final
 concentrations). Cells were incubated for six days. On day 4, fresh medium plus a
 15 fresh solution containing the test compound were added to the cell cultures. On day 6,
 the growth medium was removed by aspiration. The cells were detached by
 trypsinizing in 1.0 ml of trypsin-EDTA solution. The cell suspensions were transferred
 to 20 ml of an isotonic diluent and 0.5 ml of the diluted cell suspension was counted
 with a Coulter particle counter. Cell counts from test compound-treated cultures were
 20 normalized to cell counts obtained from DMSO-treated controls and expressed as
 percent inhibition. IC₅₀ values (concentration of test compound producing a 50%
 inhibition of cell proliferation) were derived from the inhibition data. These results are
 summarized in Table C.1.

Table C.1 : Inhibition of Smooth Muscle Cell Proliferation

Cell Line	IC ₅₀ (nM)
	Co. No. 75
A10	14
PA Σ MC	24
CASMC	16

Claims

1. A method of treating vascular proliferative disorders in a warm-blooded animal which comprises administering to said warm-blooded animal a prophylactically or therapeutically effective amount of a compound of formula (I),



- a stereoisomeric form thereof, a pharmaceutically acceptable acid or base addition salt thereof, wherein
the dotted line represents an optional bond;
X is oxygen or sulfur;
R¹ is hydrogen, C₁₋₁₂alkyl, Ar¹, Ar²C₁₋₆alkyl, quinolinylC₁₋₆alkyl, pyridylC₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkyl, mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, aminoC₁₋₆alkyl,
or a radical of formula -Alk¹-C(=O)-R⁹, -Alk¹-S(O)-R⁹ or -Alk¹-S(O)₂-R⁹, wherein Alk¹ is C₁₋₆alkanediyl,
R⁹ is hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, amino, C₁₋₈alkylamino or C₁₋₈alkylamino substituted with C₁₋₆alkyloxycarbonyl;
R², R³ and R¹⁶ each independently are hydrogen, hydroxy, halo, cyano, C₁₋₆alkyl, C₁₋₆alkyloxy, hydroxyC₁₋₆alkyloxy, C₁₋₆alkyloxyC₁₋₆alkyloxy, aminoC₁₋₆alkyloxy, mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyloxy, Ar¹, Ar²C₁₋₆alkyl, Ar²oxy, Ar²C₁₋₆alkyloxy, hydroxycarbonyl, C₁₋₆alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C₂₋₆alkenyl, 4,4-dimethyloxazolyl; or
when on adjacent positions R² and R³ taken together may form a bivalent radical of formula

-O-CH₂-O- (a-1),

-O-CH₂-CH₂-O- (a-2),

-O-CH=CH- (a-3),

-O-CH₂-CH₂- (a-4),

-O-CH₂-CH₂-CH₂- (a-5), or

-CH=CH-CH=CH- (a-6);

-47-

R⁴ and R⁵ each independently are hydrogen, halo, Ar¹, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkyl, C₁₋₆alkyloxy, C₁₋₆alkylthio, amino, hydroxycarbonyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylS(O)C₁₋₆alkyl or C₁₋₆alkylS(O)₂C₁₋₆alkyl;

5 R⁶ and R⁷ each independently are hydrogen, halo, cyano, C₁₋₆alkyl, C₁₋₆alkyloxy, Ar²oxy, trihalomethyl, C₁₋₆alkylthio, di(C₁₋₆alkyl)amino, or when on adjacent positions R⁶ and R⁷ taken together may form a bivalent radical of formula

10
$$\begin{array}{ll} -\text{O}-\text{CH}_2-\text{O}- & (\text{c-1}), \text{ or} \\ -\text{CH}=\text{CH}-\text{CH}=\text{CH}- & (\text{c-2}); \end{array}$$

R⁸ is hydrogen, C₁₋₆alkyl, cyano, hydroxycarbonyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylcarbonylC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkyloxycarbonylC₁₋₆alkyl, carboxyC₁₋₆alkyl, hydroxyC₁₋₆alkyl, aminoC₁₋₆alkyl, mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, imidazolyl, haloC₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkyl, aminocarbonylC₁₋₆alkyl, or a radical of formula

15
$$\begin{array}{ll} -\text{O}-\text{R}^{10} & (\text{b-1}), \\ -\text{S}-\text{R}^{10} & (\text{b-2}), \\ -\text{N}-\text{R}^{11}\text{R}^{12} & (\text{b-3}), \end{array}$$

20 wherein R¹⁰ is hydrogen, C₁₋₆alkyl, C₁₋₆alkylcarbonyl, Ar¹, Ar²C₁₋₆alkyl, C₁₋₆alkyloxycarbonylC₁₋₆alkyl, a radical or formula -Alk²-OR¹³ or -Alk²-NR¹⁴R¹⁵;

R¹¹ is hydrogen, C₁₋₁₂alkyl, Ar¹ or Ar²C₁₋₆alkyl;

25 R¹² is hydrogen, C₁₋₆alkyl, C₁₋₁₆alkylcarbonyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylaminocarbonyl, Ar¹, Ar²C₁₋₆alkyl, C₁₋₆alkylcarbonylC₁₋₆alkyl, a natural amino acid, Ar¹carbonyl, Ar²C₁₋₆alkylcarbonyl, aminocarbonylcarbonyl, C₁₋₆alkyloxyC₁₋₆alkylcarbonyl, hydroxy, C₁₋₆alkyloxy, aminocarbonyl, di(C₁₋₆alkyl)aminoC₁₋₆alkylcarbonyl, amino, C₁₋₆alkylamino, C₁₋₆alkylcarbonylamino, or a radical of formula -Alk²-OR¹³ or -Alk²-NR¹⁴R¹⁵;

30 wherein Alk² is C₁₋₆alkanediyl;

R¹³ is hydrogen, C₁₋₆alkyl, C₁₋₆alkylcarbonyl, hydroxyC₁₋₆alkyl, Ar¹ or Ar²C₁₋₆alkyl;

R¹⁴ is hydrogen, C₁₋₆alkyl, Ar¹ or Ar²C₁₋₆alkyl;

R¹⁵ is hydrogen, C₁₋₆alkyl, C₁₋₆alkylcarbonyl, Ar¹ or Ar²C₁₋₆alkyl;

35 R¹⁷ is hydrogen, halo, cyano, C₁₋₆alkyl, C₁₋₆alkyloxycarbonyl, Ar¹;

R¹⁸ is hydrogen, C₁₋₆alkyl, C₁₋₆alkyloxy or halo;

R¹⁹ is hydrogen or C₁₋₆alkyl;


Ar¹ is phenyl or phenyl substituted with C₁₋₆alkyl, hydroxy, amino, C₁₋₆alkyloxy or halo; and

Ar² is phenyl or phenyl substituted with C₁₋₆alkyl, hydroxy, amino, C₁₋₆alkyloxy or halo.

- 5
2. A method according to claim 1 wherein X is oxygen, the dotted line represents a bond and R¹ is hydrogen, C₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkyl or mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyl.
- 10 3. A method according to claim 1 wherein R³ is hydrogen and R² is halo, C₁₋₆alkyl, C₂₋₆alkenyl, C₁₋₆alkyloxy, trihalomethoxy or hydroxyC₁₋₆alkyloxy.
- 15 4. A method according to claim 1 wherein R⁸ is hydrogen, hydroxy, haloC₁₋₆alkyl, hydroxyC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkyloxy carbonylC₁₋₆alkyl, imidazolyl, or a radical of formula -NR¹¹R¹² wherein R¹¹ is hydrogen or C₁₋₁₂alkyl and R¹² is hydrogen, C₁₋₆alkyl, C₁₋₆alkyloxy, C₁₋₆alkyloxyC₁₋₆alkyl carbonyl, hydroxy, or a radical of formula -Alk²-OR¹³ wherein R¹³ is hydrogen or C₁₋₆alkyl.
- 20 5. A method according to claim 1 wherein the compound is (+)-6-[amino(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1*H*)-quinolinone; or a pharmaceutically acceptable acid addition salt thereof.
- 25 6. A method according to any of claims 1 to 5 wherein the vascular proliferative disorder is atherosclerosis.
7. A method according to any of claims 1 to 5 wherein the vascular proliferative disorder is restenosis.
- 30 8. A method according to any of claims 1 to 5 wherein the vascular proliferative disorder is percutaneous transluminal coronary angioplasty restenosis or coronary artery stent restenosis.
- 35 9. A method of inhibiting proliferation of smooth muscle cells in a warm-blooded animal which comprises administering to said warm-blooded animal a prophylactically or therapeutically effective amount of a compound as defined in any of claims 1 to 5.

10. A stent covered with a coating material which comprises an amount of a compound as defined in any one of claims 1 to 5 effective in preventing, treating or reducing smooth muscle cell proliferation.

5 11. Use of a compound of formula (I),



a stereoisomeric form thereof, a pharmaceutically acceptable acid or base addition salt thereof, wherein

the dotted line represents an optional bond;

X is oxygen or sulfur;

R¹ is hydrogen, C₁₋₁₂alkyl, Ar¹, Ar²C₁₋₆alkyl, quinolinylC₁₋₆alkyl, pyridylC₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkyl, mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, aminoC₁₋₆alkyl,

or a radical of formula -Alk¹-C(=O)-R⁹, -Alk¹-S(O)-R⁹ or -Alk¹-S(O)₂-R⁹, wherein Alk¹ is C₁₋₆alkanediyl,

R⁹ is hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, amino, C₁₋₈alkylamino or C₁₋₈alkylamino substituted with C₁₋₆alkyloxycarbonyl;

R², R³ and R¹⁶ each independently are hydrogen, hydroxy, halo, cyano, C₁₋₆alkyl, C₁₋₆alkyloxy, hydroxyC₁₋₆alkyloxy, C₁₋₆alkyloxyC₁₋₆alkyloxy, aminoC₁₋₆alkyloxy, mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyloxy, Ar¹, Ar²C₁₋₆alkyl, Ar²oxy, Ar²C₁₋₆alkyloxy, hydroxycarbonyl, C₁₋₆alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C₂₋₆alkenyl, 4,4-dimethyloxazolyl; or

when on adjacent positions R² and R³ taken together may form a bivalent radical of formula

-O-CH₂-O- (a-1),

-O-CH₂-CH₂-O- (a-2),

-O-CH=CH- (a-3),

-O-CH₂-CH₂- (a-4),


-O-CH₂-CH₂-CH₂- (a-5), or

-CH=CH-CH=CH- (a-6);


-50-

R⁴ and R⁵ each independently are hydrogen, halo, Ar¹, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkyl, C₁₋₆alkyloxy, C₁₋₆alkylthio, amino, hydroxycarbonyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylS(O)C₁₋₆alkyl or C₁₋₆alkylS(O)₂C₁₋₆alkyl;

- 5 R⁶ and R⁷ each independently are hydrogen, halo, cyano, C₁₋₆alkyl, C₁₋₆alkyloxy, Ar²oxy, trihalomethyl, C₁₋₆alkylthio, di(C₁₋₆alkyl)amino, or when on adjacent positions R⁶ and R⁷ taken together may form a bivalent radical of formula



- R⁸ is hydrogen, C₁₋₆alkyl, cyano, hydroxycarbonyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylcarbonylC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkyloxycarbonylC₁₋₆alkyl, carboxyC₁₋₆alkyl, hydroxyC₁₋₆alkyl, aminoC₁₋₆alkyl, mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, imidazolyl, haloC₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkyl, aminocarbonylC₁₋₆alkyl, or a radical of formula



- 20 wherein R¹⁰ is hydrogen, C₁₋₆alkyl, C₁₋₆alkylcarbonyl, Ar¹, Ar²C₁₋₆alkyl, C₁₋₆alkyloxycarbonylC₁₋₆alkyl, a radical or formula -Alk²-OR¹³ or -Alk²-NR¹⁴R¹⁵;

- R¹¹ is hydrogen, C₁₋₁₂alkyl, Ar¹ or Ar²C₁₋₆alkyl;
R¹² is hydrogen, C₁₋₆alkyl, C₁₋₆alkylcarbonyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylaminocarbonyl, Ar¹, Ar²C₁₋₆alkyl, C₁₋₆alkylcarbonylC₁₋₆alkyl, a natural amino acid, Ar¹carbonyl, Ar²C₁₋₆alkylcarbonyl, aminocarbonylcarbonyl, C₁₋₆alkyloxyC₁₋₆alkylcarbonyl, hydroxy, C₁₋₆alkyloxy, aminocarbonyl, di(C₁₋₆alkyl)aminoC₁₋₆alkylcarbonyl, amino, C₁₋₆alkylamino, C₁₋₆alkylcarbonylamino, or a radical of formula -Alk²-OR¹³ or -Alk²-NR¹⁴R¹⁵;

- 30 wherein Alk² is C₁₋₆alkanediyl;

R¹³ is hydrogen, C₁₋₆alkyl, C₁₋₆alkylcarbonyl, hydroxyC₁₋₆alkyl, Ar¹ or Ar²C₁₋₆alkyl;

R¹⁴ is hydrogen, C₁₋₆alkyl, Ar¹ or Ar²C₁₋₆alkyl;

R¹⁵ is hydrogen, C₁₋₆alkyl, C₁₋₆alkylcarbonyl, Ar¹ or Ar²C₁₋₆alkyl;

- 35 R¹⁷ is hydrogen, halo, cyano, C₁₋₆alkyl, C₁₋₆alkyloxycarbonyl, Ar¹;

R¹⁸ is hydrogen, C₁₋₆alkyl, C₁₋₆alkyloxy or halo;

R¹⁹ is hydrogen or C₁₋₆alkyl;

-51-

Ar¹ is phenyl or phenyl substituted with C₁₋₆alkyl, hydroxy, amino, C₁₋₆alkyloxy or halo; and

Ar² is phenyl or phenyl substituted with C₁₋₆alkyl, hydroxy, amino, C₁₋₆alkyloxy or halo; for the manufacture of a medicament to prevent or to treat vascular proliferative disorders.

12. Use according to claim 11 of a compound wherein X is oxygen, the dotted line represents a bond and R¹ is hydrogen, C₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkyl or mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyl.
13. Use according to any of claims 11 to 12 of a compound wherein R³ is hydrogen and R² is halo, C₁₋₆alkyl, C₂₋₆alkenyl, C₁₋₆alkyloxy, trihalomethoxy or hydroxyC₁₋₆alkyloxy.
14. Use according to any of claims 11 to 13 of a compound wherein R⁸ is hydrogen, hydroxy, haloC₁₋₆alkyl, hydroxyC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkyloxycarbonylC₁₋₆alkyl, imidazolyl, or a radical of formula -NR¹¹R¹² wherein R¹¹ is hydrogen or C₁₋₁₂alkyl and R¹² is hydrogen, C₁₋₆alkyl, C₁₋₆alkyloxy, C₁₋₆alkyloxyC₁₋₆alkylcarbonyl, hydroxy, or a radical of formula -Alk²-OR¹³ wherein R¹³ is hydrogen or C₁₋₆alkyl.
15. Use according to claim 11 of wherein the compound is (+)-6-[amino(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1*H*)-quinolinone; or a pharmaceutically acceptable acid addition salt thereof.
16. Use according to any of claims 11 to 15 wherein the vascular proliferative disorder is atherosclerosis.
17. Use according to any of claims 11 to 15 wherein the vascular proliferative disorder is restenosis.
18. Use according to any of claims 11 to 15 wherein the vascular proliferative disorder is percutaneous transluminal coronary angioplasty restenosis or coronary artery stent restenosis.
19. Use of a compound of formula (I) as defined in any of claims 11 to 15, for the manufacture of a medicament for the inhibition of smooth muscle cell proliferation.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/03182

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/47

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbol/s)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y, P	WO 97 21701 A (JANSSEN PHARMACEUTICA NV ; VENET MARC GASTON (FR); ANGIBAUD PATRICK) 19 June 1997 cited in the application see page 16, line 24 - page 17, line 25 ---	1-19
Y	INDOLFI ET AL.: "inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo" NATURE MEDICINE, vol. 1, 1995, pages 541-545, XP002077097 cited in the application see page 542, right-hand column, paragraph 2 --- -/--	1-19



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

10 September 1998

Date of mailing of the international search report

23/09/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Trifilieff-Riolo, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/03182

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>IRANI ET AL.: "ras proteins regulate multiple mitogenic pathways in a10 vascular smooth muscle cells" BIOCHEM. AND BIOPHYS. RES. COMM., vol. 202, no. 3, 1994, pages 1252-1258, XP002077098 cited in the application see page 1257</p> <p style="text-align: center;">-----</p>	1-19

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 98/03182

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 1-9
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/03182

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9721701 A	19-06-1997	AU 7294896 A	03-07-1997
		HR 960576 A	28-02-1998
		NO 980927 A	08-06-1998
<hr/>			